# Goldman Sachs Funds

Semi-Annual Financial Statements	February 28, 2025
	Goldman Sachs Future Thematic Equity ETFs Goldman Sachs Future Consumer Equity ETF (GBUY) Goldman Sachs Future Health Care Equity ETF (GDOC) Goldman Sachs Future Planet Equity ETF (GSFP) Goldman Sachs Future Tech Leaders Equity ETF (GTEK)

Goldman Asset Sachs Management

# Goldman Sachs Future Thematic Equity ETFs

Table of Contents	Page
Schedules of Investments	
Goldman Sachs Future Consumer Equity ETF	3
Goldman Sachs Future Health Care Equity ETF	4
Goldman Sachs Future Planet Equity ETF	6
Goldman Sachs Future Tech Leaders Equity ETF	8
Financial Statements	
Statements of Assets and Liabilities	10
Statements of Operations	11
Statements of Changes in Net Assets	12
Financial Highlights	
Goldman Sachs Future Consumer Equity ETF	14
Goldman Sachs Future Health Care Equity ETF	15
Goldman Sachs Future Planet Equity ETF	16
Goldman Sachs Future Tech Leaders Equity ETF	17
Notes to Financial Statements	18

February 28, 2025 (Unaudited)

4,219       CTS Eventim AG & Co. KGaA (Germany)       463,348         5,558       Live Nation Entertainment, Inc.*       796,795         3,186       Meta Platforms, Inc., Class A       2,128,885         9,160       NetEase, Inc. (China)       182,340         1,328       Netflix, Inc.*       1,302,184         1,329       Sea Ltd. ADR (Singapore)*       240,668         1,344       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       509,526         14,144       Tencent Music Entertainment Group ADR (China)       172,415         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Consumer Discretionary - 24.0%       12,839         12,839       Amazon.com, Inc.*       2,725,463         12,839       Amazon.com, Inc.*       2,725,463         12,849       Bosideng International Holdings       106,492         748,000       Bosideng International Ho	Shares	Description	Value
11,734       Alphabet, Inc., Class C       \$       2,020,829         4,219       CTS Eventim AG & Co. KGaA       (Germany)       463,348         5,558       Live Nation Entertainment, Inc., Class A       2,128,885         9,160       NetEase, Inc. (China)       1,82,340         1,328       Netflix, Inc.*       1,302,184         1,328       Netflix, Inc.*       1,302,184         1,328       Netflix, Inc.*       1,302,184         1,344       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       172,415         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       10,451,795         Consumer Discretionary - 24.0%       12,839       Amazon.com, Inc.*         12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)*(**)       106,492         748,000       Bosideng International Holdings       104,451,795         Consumer Discretionary - 24.0%       2,725,463       1,281         1,281       Home Depot, Inc. (The)       508,045       1,642         1,285       Livit (China)       364,550       1,285	Common Stock	cs – 98.5%	
4,219       CTS Eventim AG & Co. KGaA (Germany)       463,348         5,558       Live Nation Entertainment, Inc., *       796,795         3,186       Meta Platforms, Inc., Class A       2,128,885         9,160       NetEase, Inc. (China)       182,340         1,328       Netflix, Inc.*       1,302,184         1,891       Sea Ltd. ADR (Singapore)*       240,668         1,344       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       172,415         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Consumer Discretionary - 24.0%       12,839         12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)*(**)       106,492         748,000       Bosideng International Holdings       Ltd. (China)         12,839       Amazon.com, Inc.*       123,349         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       Vuitton SE (France)       928,665         16,761       Meituan, Class B (China)**       373,449	Communication	Services – 29.3%	
(Germany)         463,348           5,558         Live Nation Entertainment, Inc.*         796,795           3,186         Meta Platforms, Inc., Class A         2,128,885           9,160         NetEase, Inc. (China)         1,302,184           1,328         Netflix, Inc.*         1,302,184           1,328         Netflix, Inc.*         1,302,184           1,344         Spotify Technology SA*         817,165           8,279         Tencent Holdings Ltd. (China)         509,526           14,144         Tencent Music Entertainment Group ADR (China)         172,415           3,675         T-Mobile US, Inc.         991,111           7,263         Walt Disney Co. (The)         826,529           10,451,795         Consumer Discretionary - 24.0%         12,839           12,839         Amazon.com, Inc.*         2,725,463           4,452         Basic-Fit NV (Netherlands)*(*0)         106,492           748,000         Bosideng International Holdings         123,349           Ltd. (China)         364,550         1,298         Cava Group, Inc.*         123,349           12,853         Chipotle Mexican Grill, Inc.*         693,676         149,165           1,285         LVMH Moet Hennessy Louis         Yuitton SE (France)			\$ 2,020,829
5,558       Live Nation Entertainment, Inc.*       796,795         3,186       Meta Platforms, Inc., Class A       2,128,885         9,160       NetEase, Inc. (China)       1,302,184         1,328       Netflix, Inc.*       1,302,184         1,891       Sea Ltd. ADR (Singapore)*       1,302,184         1,844       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       509,526         14,144       Tencent Music Entertainment       509,526         16,144       Tencent Music Entertainment       509,526         16,757       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Consumer Discretionary - 24.0%       12,839         12,839       Amazon.com, Inc.*       2,725,463         1,4452       Basic-Fit NV (Netherlands)*(**)       106,492         748,000       Bosideng International Holdings       106,492         14,014       Cava Group, Inc.*       123,344         12,851       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       373,449         1,669       Monc	4,219		463 348
3,186       Meta Platforms, Inc., Class A       2,128,885         9,160       NetEase, Inc. (China)       1,302,184         1,328       Netflix, Inc.*       1,302,184         1,328       Netflix, Inc.*       1,302,184         1,344       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       509,526         14,144       Tencent Holdings Ltd. (China)       172,415         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Consumer Discretionary - 24.0%       12,839         12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)* <sup>(a)</sup> 106,492         748,000       Bosideng International Holdings       123,349         12,833       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,645         1,282       L/M Hoet Hennessy Louis       73,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630	5 558		
9,160       NetEase, Inc. (China)       182,340         1,328       Netflix, Inc.*       1,302,184         1,891       Sea Ltd. ADR (Singapore)*       240,668         1,344       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       509,526         14,144       Tencent Music Entertainment       Group ADR (China)       172,415         3,675       T-Mobile US, Inc.       991,111       7,263         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Consumer Discretionary - 24.0%       106,492         748,000       Bosideng International Holdings       106,492         748,000       Bosideng International Holdings       123,349         12,833       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       Yuitton SE (France)       928,665         16,674       Meituan, Class B (China)**       349,165       373,449         6,694       Moncler SpA (Italy)       460,312       2,676         2,676       Planet Fitness, Inc., Class A*       247,664       69,089       Shenzho	· · · · ·	· · · · · · · · · · · · · · · · · · ·	,
1,328       Netflix, Inc.*       1,302,184         1,891       Sea Ltd. ADR (Singapore)*       240,668         1,344       Spotify Technology SA*       817,165         8,279       Tencent Holdings Ltd. (China)       509,526         14,144       Tencent Music Entertainment       Group ADR (China)       172,415         3,675       T-Mobile US, Inc.       991,111       72,63         7,263       Walt Disney Co. (The)       826,529       10,451,795         Consumer Discretionary - 24.0%       2,725,463       106,492         12,839       Amazon com, Inc.*       2,725,463       106,492         748,000       Bosideng International Holdings Ltd. (China)       364,550       1,238         1,281       Home Depot, Inc. (The)       508,045       1,233,49         1,285       LVMH Moet Hennessy Louis       Vuitton SE (France)       928,665         16,761       Meituan, Class B (China)* <sup>(a)</sup> 349,165       176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312       2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United			
1,344       Spotify Technology SA* $817,165$ 8,279       Tencent Holdings Ltd. (China) $509,526$ 14,144       Tencent Music Entertainment $509,526$ 13,675       TMobile US, Inc. $991,111$ 7,263       Walt Disney Co. (The) $826,529$ 10,451,795       Consumer Discretionary - 24.0%       10,451,795         Consumer Discretionary - 24.0%       106,492         748,000       Bosideng International Holdings       106,492         748,000       Bosideng International Group       938,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664			1,302,184
8,279       Tencent Holdings Ltd. (China)       509,526         14,144       Tencent Music Entertainment       172,415         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       10,451,795         Consumer Discretionary - 24.0%       12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)* <sup>(a)</sup> 106,492         748,000       Bosideng International Holdings       106,492         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       Vuitton SE (France)       928,665         16,761       Meituan, Class B (China)* <sup>(a)</sup> 349,165       176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312       2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116       172,528         157,528       Budweiser Brewing Co. APAC Ltd. (China)       168,740       1,673       <	1,891	Sea Ltd. ADR (Singapore)*	240,668
14,144       Tencent Music Entertainment       172,415         3,675       T-Mobile US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Tombule US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Tombule US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Tombule US, Inc.       991,111         7,263       Walt Disney Co. (The)       826,529         10,451,795       Tombule US, Inc.       991,111         7,263       Walt Disney Co. (The)       10,451,795         Consumer Discretionary - 24.0%       2,725,463       106,492         748,000       Bosideng International Holdings Ltd. (China)       364,550         1,281       Home Depot, Inc. (The)       508,045       12,853         1,285       LVMH Moet Hennessy Louis Vuitton SE (France)       928,665       16,761       MetcadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,315       460,316       460,436         2,676       Planet Fitness, Inc., Class A*       247,664       69,089       Shenzhou International Group Holdings Ltd. (China)       504,630			817,165
Group ADR (China)         172,415           3,675         T-Mobile US, Inc.         991,111           7,263         Walt Disney Co. (The) $826,529$ 10,451,795         10,451,795           Consumer Discretionary – 24.0%         10,451,795           12,839         Amazon.com, Inc.*         2,725,463           4,452         Basic-Fit NV (Netherlands)* <sup>(a)</sup> 106,492           748,000         Bosideng International Holdings         104,517.95           Ltd. (China)         364,550         1,298         Cava Group, Inc.*         123,349           12,853         Chipotle Mexican Grill, Inc.*         693,676         1,281         Home Depot, Inc. (The)         508,045           1,285         LVMH Moet Hennessy Louis         Vuitton SE (France)         928,665         16,761         Meituan, Class B (China)*(a)         349,165           1,76         MercadoLibre, Inc. (Brazil)*         373,449         6,694         Moncler SpA (Italy)         460,312           2,676         Planet Fitness, Inc., Class A*         247,664         69,089         Shenzhou International Group           Holdings Ltd. (China)         504,630         383,095         Talabat Holding PLC (United Arab Emirates)*         160,635           8,116         TJX Cos., Inc. (The)			509,526
$\begin{array}{c} 3,675 \ \text{T-Mobile US, Inc.} \\ 991,111 \\ 7,263 \ \text{Walt Disney Co. (The)} \\ \hline 826,529 \\ \hline 10,451,795 \\ \hline \\ $	14,144		
7,263       Walt Disney Co. (The) $826,529$ 10,451,795       10,451,795         Consumer Discretionary – 24.0%       12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)* <sup>(a)</sup> 106,492         748,000       Bosideng International Holdings       106,492         12,833       Chipotle Mexican Grill, Inc.*       693,670         1,284       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       Vuitton SE (France)       928,665         16,761       Meituan, Class B (China)* <sup>(a)</sup> 349,165       176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312       2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116       1012,552         8,116       TJX Cos., Inc. (The)       1,012,552       8,558,647          Icd. (China)       661,434         2,462       Oddity Tech Ltd., Class A       (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A       1,60			172,415
10,451,795           Consumer Discretionary – 24.0%           12,839         Amazon.com, Inc.*         2,725,463           4,452         Basic-Fit NV (Netherlands)*(a)         106,492           748,000         Bosideng International Holdings         12,833           Ltd. (China)         364,550           1,298         Cava Group, Inc.*         12,3349           12,853         Chipotle Mexican Grill, Inc.*         693,676           1,281         Home Depot, Inc. (The)         508,045           1,285         LVMH Moet Hennessy Louis         Vuitton SE (France)         928,665           16,761         Meituan, Class B (China)*(a)         349,165         176           176         MercadoLibre, Inc. (Brazil)*         373,449         6,694           6,694         Moncler SpA (Italy)         460,312         2,676           2,676         Planet Fitness, Inc., Class A*         247,664           69,089         Shenzhou International Group         Holdings Ltd. (China)         504,630           383,095         Talabat Holding PLC (United Arab Emirates)*         160,635         8,116           157,528         Budweiser Brewing Co. APAC Ltd. (China)         168,740         1,673           1,673         elf Beauty, In			991,111
Consumer Discretionary – 24.0%         12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)*(a)       106,492         748,000       Bosideng International Holdings       123,349         12,853       Chipotle Mexican Grill, Inc.*       123,349         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116         7JX Cos., Inc. (The)       1,012,552       8,558,647         Consumer Staples – 3.5%       157,528       Budweiser Brewing Co. APAC Ltd. (China)       661,434         2,462       Oddity Tech Ltd., Class A (Israel)*       117,241       168,740         1,673       elf Beauty, Inc.*       117,241       166,67,	7,263	Walt Disney Co. (The)	826,529
12,839       Amazon.com, Inc.*       2,725,463         4,452       Basic-Fit NV (Netherlands)*(a)       106,492         748,000       Bosideng International Holdings       123,349         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,285       Civiton E (France)       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116         7JX Cos., Inc. (The)       1,012,552       8,558,647         Consumer Staples - 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China)       661,434         2,462       Oddity Tech Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       12,256,796         Financials - 5.3%         117,104       Jio Financial Services Ltd. (India)			10,451,795
4,452       Basic-Fit NV (Netherlands)*(a)       106,492         748,000       Bosideng International Holdings       123,349         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       Vuitton SE (France)       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116       TJX Cos., Inc. (The)       1,012,552         8,516       TJX Cos., Inc. (The)       1,012,552       8,558,647         Consumer Staples - 3.5%         157,528       Budweiser Brewing Co. APAC       117,528         1,673       elf Beauty, Inc.*       117,528       3,214         Kweichow Moutai Co. Ltd., Class A (Israel)*       117,241       16,577       Proya Cosmetics Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., C	Consumer Discre	tionary – 24.0%	
748,000       Bosideng International Holdings         Ltd. (China)       364,550         1,298       Cava Group, Inc.*       123,349         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       508,045         1,285       LVMH Moet Hennessy Louis       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United       Arab Emirates)*       160,635         8,116       TJX Cos., Inc. (The)       1,012,552       8,558,647          168,740       168,740         157,528       Budweiser Brewing Co. APAC       117,528         157,528       Budweiser Brewing Co. APAC       117,528         3,214       Kweichow Moutai Co. Ltd.,       117,528         3,214       Kweichow Moutai Co. Ltd.,       12,56,796	12,839	Amazon.com, Inc.*	2,725,463
Ltd. (China) $364,550$ 1,298       Cava Group, Inc.* $123,349$ 12,853       Chipotle Mexican Grill, Inc.* $693,676$ 1,281       Home Depot, Inc. (The) $508,045$ 1,285       LVMH Moet Hennessy Louis $Vuitton SE$ (France) $928,665$ 16,761       Meituan, Class B (China)* <sup>(a)</sup> $349,165$ $349,165$ 176       MercadoLibre, Inc. (Brazil)* $373,449$ 6,694       Moncler SpA (Italy) $460,312$ 2,676       Planet Fitness, Inc., Class A* $247,664$ 69,089       Shenzhou International Group       Holdings Ltd. (China) $504,630$ 383,095       Talabat Holding PLC (United Arab Emirates)* $160,635$ $8,116$ $17JX$ Cos., Inc. (The) $1,012,552$ 8,516       TJX Cos., Inc. (The) $1,012,552$ $8,558,647$ Consumer Staples – $3.5\%$ $157,528$ Budweiser Brewing Co. APAC $1,613,434$ $1,673$ elf Beauty, Inc.* $117,528$ $3,214$ Kweichow Moutai Co. Ltd., Class A $117,241$ $16,577$ Proya Cosmetics Co. Ltd., Class A $12,256,796$ $117,104$ $105$ Financial Services Ltd. (India)* $277,839$ <			106,492
1,298       Cava Group, Inc.*       123,349         12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116         7JX Cos., Inc. (The)       1,012,552       8,558,647         Consumer Staples – 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China)       168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         17,104       Jio Financial Services Ltd. (India)*       277,839         2,787       M	748,000		
12,853       Chipotle Mexican Grill, Inc.*       693,676         1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116       TJX Cos., Inc. (The)       1,012,552         8,558,647       Expression (Co. APAC Ltd. (China) <sup>(a)</sup> 168,740       1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (Israel)*       117,241       16,577       Proya Cosmetics Co. Ltd., Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A (China)       191,853       1,256,796         Financials - 5.3%       117,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176       1,884,015         Health Care - 1.3%       4,913       Cooper Cos., Inc. (The)			364,550
1,281       Home Depot, Inc. (The)       508,045         1,285       LVMH Moet Hennessy Louis       Vuitton SE (France)       928,665         16,761       Meituan, Class B (China)* <sup>(a)</sup> 349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Foldings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116         7JX Cos., Inc. (The)       1,012,552       8,558,647         Consumer Staples - 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> 168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         117,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176         1,884,015       Health Care - 1.3%       4,913       Cooper Cos., Inc. (The)*       444,037         Industrials - 1.7%			· · · · ·
1,285       LVMH Moet Hennessy Louis       928,665         16,761       Meituan, Class B (China)*(a)       349,165         176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635       8,116         7JX Cos., Inc. (The)       1,012,552       8,558,647         Consumer Staples – 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China)       168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         117,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176         1,884,015       Health Care – 1.3%       4,913       Cooper Cos., Inc. (The)*         4,913       Cooper Cos., Inc. (The)*       444,037 <td></td> <td></td> <td>· · · · ·</td>			· · · · ·
Vuitton SE (France)       928,665         16,761 Meituan, Class B (China)*(a)       349,165         176 MercadoLibre, Inc. (Brazil)*       373,449         6,694 Moncler SpA (Italy)       460,312         2,676 Planet Fitness, Inc., Class A*       247,664         69,089 Shenzhou International Group Holdings Ltd. (China)       504,630         383,095 Talabat Holding PLC (United Arab Emirates)*       160,635         8,116 TJX Cos., Inc. (The)       1,012,552         8,558,647       8,558,647         Consumer Staples – 3.5%         157,528 Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> 168,740         1,673 elf Beauty, Inc.*       117,528         3,214 Kweichow Moutai Co. Ltd., Class A (China)       661,434         2,462 Oddity Tech Ltd., Class A (Israel)*       117,241         16,577 Proya Cosmetics Co. Ltd., Class A (China)       191,853         117,104 Jio Financial Services Ltd. (India)*       277,839         2,787 Mastercard, Inc., Class A       1,606,176         1,84,015       1,844,015         Health Care – 1.3%         4,913 Cooper Cos., Inc. (The)*       444,037         Industrials – 1.7%       444,037			508,045
16,761       Meituan, Class B (China)*(a) $349,165$ 176       MercadoLibre, Inc. (Brazil)* $373,449$ 6,694       Moncler SpA (Italy) $460,312$ 2,676       Planet Fitness, Inc., Class A* $247,664$ 69,089       Shenzhou International Group       Holdings Ltd. (China) $504,630$ 383,095       Talabat Holding PLC (United Arab Emirates)* $160,635$ $8,116$ $1,012,552$ 8,116       TJX Cos., Inc. (The) $1,012,552$ $8,558,647$ Consumer Staples – $3.5\%$ 157,528       Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> $168,740$ 1,673       elf Beauty, Inc.* $117,528$ 3,214       Kweichow Moutai Co. Ltd., Class A (China) $661,434$ 2,462       Oddity Tech Ltd., Class A (China) $191,853$ 16,577       Proya Cosmetics Co. Ltd., Class A (China) $191,853$ 117,104       Jio Financial Services Ltd. (India)* $277,839$ 2,787       Mastercard, Inc., Class A $1,606,176$ 1,840,015       Health Care – $1.3\%$ $4,913$ Cooper Cos., Inc. (The)* $444,037$	1,285		000 ((5
176       MercadoLibre, Inc. (Brazil)*       373,449         6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635         8,116       TJX Cos., Inc. (The)       1,012,552         8,558,647       8,558,647         Consumer Staples – 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China) <sup>(6)</sup> 168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         117,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176         1,844,015       1,844,015         Health Care – 1.3%       4,913       Cooper Cos., Inc. (The)*         444,037       Industrials – 1.7%       444,037	16761		
6,694       Moncler SpA (Italy)       460,312         2,676       Planet Fitness, Inc., Class A*       247,664         69,089       Shenzhou International Group       100,635         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635         8,116       TJX Cos., Inc. (The)       1,012,552         8,558,647       8,558,647         Consumer Staples – 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China) <sup>(6)</sup> 168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         17,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176         1,84,015       1,844,015         Health Care – 1.3%         4,913       Cooper Cos., Inc. (The)*       444,037         Industrials – 1.7%       444,037			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			,
69,089       Shenzhou International Group Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United Arab Emirates)*       160,635         8,116       TJX Cos., Inc. (The) $1,012,552$ 8,558,647       8,558,647         Consumer Staples – 3.5%         157,528       Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> 168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         117,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176         1,884,015       Health Care – 1.3%       4,913       Cooper Cos., Inc. (The)*       444,037         Industrials – 1.7%       10       10       10       10       10			· · · · ·
Holdings Ltd. (China)       504,630         383,095       Talabat Holding PLC (United         Arab Emirates)*       160,635         8,116       TJX Cos., Inc. (The) $1,012,552$ 8,558,647       8,558,647         Consumer Staples – 3.5%         157,528       Budweiser Brewing Co. APAC         Ltd. (China) <sup>(a)</sup> 168,740         1,673       elf Beauty, Inc.*         3,214       Kweichow Moutai Co. Ltd.,         Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A         (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class         A (China)       191,853         117,104       Jio Financial Services Ltd.         (India)*       277,839         2,787       Mastercard, Inc., Class A         4,913       Cooper Cos., Inc. (The)*         Health Care – 1.3%       444,037         Industrials – 1.7%       444,037			247,004
$\begin{array}{c} 383,095 \ \mbox{Talabat Holding PLC (United Arab Emirates)*} & 160,635 \\ 8,116 \ \mbox{TJX Cos., Inc. (The)} & 1,012,552 \\ 8,558,647 \\ \hline \mbox{Consumer Staples - 3.5\%} & \\ 157,528 \ \mbox{Budweiser Brewing Co. APAC Ltd. (China)^{(a)} & 168,740 \\ 1,673 \ \mbox{elf Beauty, Inc.*} & 117,528 \\ 3,214 \ \mbox{Kweichow Moutai Co. Ltd., Class A (China) & 661,434 \\ 2,462 \ \mbox{Odity Tech Ltd., Class A (Israel)* & 117,241 \\ 16,577 \ \mbox{Proya Cosmetics Co. Ltd., Class A (China) & 191,853 \\ 1,256,796 \\ \hline \mbox{Financials - 5.3\%} & \\ 117,104 \ \mbox{Jio Financial Services Ltd. (India)* & 277,839 \\ 2,787 \ \mbox{Mastercard, Inc., Class A & 1,606,176 \\ 1,884,015 \\ \hline \mbox{Health Care - 1.3\% & 4,913 \ \ \mbox{Cooper Cos., Inc. (The)* & 444,037 \\ \hline \mbox{Industrials - 1.7\%} \\ \hline \end{array}$	0,007		504 630
Arab Emirates)*       160,635 $8,116$ TJX Cos., Inc. (The) $1,012,552$ $8,558,647$ Consumer Staples - 3.5% $8,558,647$ I 57,528 Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> 168,740 $1,673$ elf Beauty, Inc.*       117,528 $3,214$ Kweichow Moutai Co. Ltd., Class A (China)       661,434 $2,462$ Oddity Tech Ltd., Class A (Israel)*       117,241 $16,577$ Proya Cosmetics Co. Ltd., Class A (China)       191,853 $1,256,796$ 117,104 Jio Financial Services Ltd. (India)*       277,839 $2,787$ Mastercard, Inc., Class A       1,606,176 $1,884,015$ 1,884,015         Health Care - 1.3%       4,913 Cooper Cos., Inc. (The)*       444,037	383 095		504,050
$8,116$ TJX Cos., Inc. (The) $1,012,552$ $8,558,647$ Consumer Staples - 3.5% $157,528$ Budweiser Brewing Co. APAC         Ltd. (China) <sup>(a)</sup> $168,740$ $1,673$ elf Beauty, Inc.* $117,528$ $3,214$ Kweichow Moutai Co. Ltd.,       Class A (China) $Class A$ (China) $661,434$ $2,462$ Oddity Tech Ltd., Class A $(1577)$ Proya Cosmetics Co. Ltd., Class         A (China) $191,853$ $1,256,796$ Financials - 5.3% $117,104$ Jio Financial Services Ltd. $(India)^*$ $277,839$ $2,787$ Mastercard, Inc., Class A $1,606,176$ $1,884,015$ Health Care - 1.3% $4,913$ Cooper Cos., Inc. (The)* $444,037$	565,075		160 635
8,558,647           Consumer Staples – 3.5%           157,528         Budweiser Brewing Co. APAC           Ltd. (China) <sup>(a)</sup> 168,740           1,673         elf Beauty, Inc.*           3,214         Kweichow Moutai Co. Ltd., Class A (China)         661,434           2,462         Oddity Tech Ltd., Class A         661,434           2,462         Oddity Tech Ltd., Class A         117,241           16,577         Proya Cosmetics Co. Ltd., Class A         191,853           A (China)         191,853           1,256,796         1,256,796           Financials - 5.3%           117,104         Jio Financial Services Ltd. (India)*         277,839           2,787         Mastercard, Inc., Class A         1,606,176           1,884,015         1,884,015           Health Care - 1.3%         4,913         Cooper Cos., Inc. (The)*           Houstrials - 1.7%         444,037	8.116	,	· · · · ·
Consumer Staples - 3.5%           157,528         Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> 1,673         elf Beauty, Inc.*           3,214         Kweichow Moutai Co. Ltd., Class A (China)           2,462         Oddity Tech Ltd., Class A (Israel)*           117,241           16,577           Proya Cosmetics Co. Ltd., Class A (China)           191,853           1,256,796           Financials - 5.3%           117,104           Jio Financial Services Ltd. (India)*           2,787           Mastercard, Inc., Class A           4,913           Cooper Cos., Inc. (The)*           444,037	- , -		
157,528       Budweiser Brewing Co. APAC Ltd. (China) <sup>(a)</sup> 168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd., Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A (Israel)*       117,241         16,577       Proya Cosmetics Co. Ltd., Class A (China)       191,853         1,256,796       117,104       Jio Financial Services Ltd. (India)*       277,839         2,787       Mastercard, Inc., Class A       1,606,176         1,884,015       1,884,015         Health Care - 1.3%       4,913       Cooper Cos., Inc. (The)*         Industrials - 1.7%       1.7%	Consumer Stanle	25 – 3 5%	-,,-
Ltd. (China) <sup>(a)</sup> 168,740         1,673       elf Beauty, Inc.*       117,528         3,214       Kweichow Moutai Co. Ltd.,       Class A (China)         Class A (China)       661,434         2,462       Oddity Tech Ltd., Class A       117,241         16,577       Proya Cosmetics Co. Ltd., Class       191,853         A (China)       191,853       1,256,796         Financials - 5.3%       117,104       Jio Financial Services Ltd.       1,606,176         1,884,015       1,884,015       1,884,015       1,884,015         Health Care - 1.3%       4,913       Cooper Cos., Inc. (The)*       444,037	-		
1,673 elf Beauty, Inc.*       117,528         3,214 Kweichow Moutai Co. Ltd.,       Class A (China)         2,462 Oddity Tech Ltd., Class A       661,434         2,462 Oddity Tech Ltd., Class A       117,241         16,577 Proya Cosmetics Co. Ltd., Class       191,853         A (China)       191,853         1,256,796       117,104         Financials - 5.3%       2,787         117,104 Jio Financial Services Ltd.       1,606,176         1,884,015       1,884,015         Health Care - 1.3%       4,913         4,913 Cooper Cos., Inc. (The)*       444,037	157,520	I td (China) <sup>(a)</sup>	168 740
$\begin{array}{c} 3,214 \ \text{Kweichow Moutai Co. Ltd.,} \\ Class A (China) & 661,434 \\ 2,462 \ Oddity Tech Ltd., Class A \\ (Israel)* & 117,241 \\ 16,577 \ Proya Cosmetics Co. Ltd., Class A \\ A (China) & 191,853 \\ 1,256,796 \\ \hline \\ \textbf{Financials - 5.3\%} \\ 117,104 \ \text{Jio Financial Services Ltd.} \\ (India)* & 277,839 \\ 2,787 \ \text{Mastercard, Inc., Class A} & 1,606,176 \\ \hline 1,884,015 \\ \hline \\ \textbf{Health Care - 1.3\%} \\ 4,913 \ Cooper Cos., Inc. (The)* & 444,037 \\ \hline \\ \textbf{Industrials - 1.7\%} \\ \hline \end{array}$	1.673		
Class A (China) 661,434 2,462 Oddity Tech Ltd., Class A (Israel)* 117,241 16,577 Proya Cosmetics Co. Ltd., Class A (China) 191,853 1,256,796 Financials - 5.3% 117,104 Jio Financial Services Ltd. (India)* 277,839 2,787 Mastercard, Inc., Class A 1,606,176 1,884,015 Health Care - 1.3% 4,913 Cooper Cos., Inc. (The)* 444,037 Industrials - 1.7%	· · · · ·		11,,020
2,462 Oddity Tech Ltd., Class A (Israel)* 117,241 16,577 Proya Cosmetics Co. Ltd., Class A (China) 191,853 1,256,796 Financials - 5.3% 117,104 Jio Financial Services Ltd. (India)* 277,839 2,787 Mastercard, Inc., Class A 1,606,176 1,884,015 Health Care - 1.3% 4,913 Cooper Cos., Inc. (The)* 444,037 Industrials - 1.7%	- ,		661,434
16,577       Proya Cosmetics Co. Ltd., Class         A (China)       191,853         1,256,796         Financials - 5.3%         117,104       Jio Financial Services Ltd. (India)*         2,787       Mastercard, Inc., Class A         1,606,176         1,884,015         Health Care - 1.3%         4,913       Cooper Cos., Inc. (The)*         1ndustrials - 1.7%	2,462		,
A (China) 191,853 1,256,796 Financials - 5.3% 117,104 Jio Financial Services Ltd. (India)* 277,839 2,787 Mastercard, Inc., Class A 1,606,176 1,884,015 Health Care - 1.3% 4,913 Cooper Cos., Inc. (The)* 444,037 Industrials - 1.7%		(Israel)*	117,241
1,256,796         1,256,796         1,256,796         1,256,796         1,256,796         1,256,796         1,256,796         1,256,796         1,17,104 Jio Financial Services Ltd. (India)*         2,77,839         2,787 Mastercard, Inc., Class A         1,606,176         1,844,015         Health Care – 1.3%         4,913 Cooper Cos., Inc. (The)*         4444,037         Industrials – 1.7%	16,577	Proya Cosmetics Co. Ltd., Class	
Financials - 5.3%       117,104 Jio Financial Services Ltd. (India)*       277,839         2,787 Mastercard, Inc., Class A       1,606,176         1,884,015       1,884,015         Health Care - 1.3%       4,913 Cooper Cos., Inc. (The)*         444,037       Industrials - 1.7%		A (China)	191,853
117,104 Jio Financial Services Ltd. (India)*       277,839         2,787 Mastercard, Inc., Class A       1,606,176         1,884,015       1,884,015         Health Care – 1.3%       4,913 Cooper Cos., Inc. (The)*         444,037       1ndustrials – 1.7%			1,256,796
117,104 Jio Financial Services Ltd. (India)*       277,839         2,787 Mastercard, Inc., Class A       1,606,176         1,884,015       1,884,015         Health Care – 1.3%       4,913 Cooper Cos., Inc. (The)*         444,037       1ndustrials – 1.7%	Financials – 5.3%	6	
(India)* 277,839 2,787 Mastercard, Inc., Class A 1,606,176 1,884,015 Health Care – 1.3% 4,913 Cooper Cos., Inc. (The)* 444,037 Industrials – 1.7%			
2,787 Mastercard, Inc., Class A 1,606,176 1,884,015 Health Care – 1.3% 4,913 Cooper Cos., Inc. (The)* 444,037 Industrials – 1.7%	.,		277,839
Health Care – 1.3%         4,913 Cooper Cos., Inc. (The)*         444,037           Industrials – 1.7%         444,037	2,787	Mastercard, Inc., Class A	1,606,176
Health Care – 1.3%         4,913 Cooper Cos., Inc. (The)*         444,037           Industrials – 1.7%         444,037			
4,913 Cooper Cos., Inc. (The)* 444,037	Health Care – 1	3%	<u> </u>
Industrials – 1.7%			444.037
		,	
12,536 Experian FLC 585,700			505 700
	12,338		585,700

Shares	Description	Value
Common Stoc	ks – (continued)	
Information Tech	nnology – 28.0%	
14,401	Apple, Inc. \$	3,482,738
15,690	Infineon Technologies AG	
	(Germany)	579,438
,	Marvell Technology, Inc.	795,253
	NVIDIA Corp.	2,708,641
8,864	Samsung Electronics Co. Ltd.	
	(South Korea)	330,226
	Shopify, Inc., Class A (Canada)*	561,680
47,342	Taiwan Semiconductor	
	Manufacturing Co. Ltd. (Taiwan)	1,500,516
		9,958,492
Materials – 1.8%	6	
6,055	DSM-Firmenich AG	
	(Switzerland)	648,612
Real Estate – 1.7	7%	
2,984	American Tower Corp. REIT	613,570
Utilities – 1.9%		
9,670	NextEra Energy, Inc.	678,544
TOTAL COMMO	DN STOCKS	
(Cost \$29,686,	,376)	35,080,208
Shares	Dividend Rate	Value
Investment Co	mpany – 1.1% <sup>(b)</sup>	
Goldman Sach	s Financial Square Treasury	
Obligations	Fund – Institutional Shares	
401,970	4.253%	401,970
(Cost \$401,97	0)	
TOTAL INVEST	MENTS – 99.6%	
(Cost \$30.088.	.346) \$	35 482 178

(Cost \$30,088,346)	\$ 35,482,178
OTHER ASSETS IN EXCESS OF LIABILITIES	
- 0.4%	145,723
NET ASSETS – 100.0%	\$ 35,627,901

The percentage shown for each investment category reflects the value of investments in that category as a percentage of net assets.

\* Non-income producing security.

(a) Exempt from registration under Rule 144A of the Securities Act of 1933.(b) Represents an affiliated issuer.

Investment Abbreviations:	
ADR	<ul> <li>—American Depositary Receipt</li> </ul>
PLC	-Public Limited Company
REIT	-Real Estate Investment Trust

February 28, 2025 (Unaudited)

Common Stocks – 98.5%           Canada – 0.7%           3,859 Xenon Pharmaceuticals, Inc. (Health Care)*         \$ 142,860           Denmark – 3.8%         9,050 Novo Nordisk A/S, Class B (Health Care)         813,388           France – 0.8%         771 Sartorius Stedim Biotech (Health Care)         159,566           Germany – 1.0%         1,812 BioNTech SE ADR (Health Care)*         204,611           Japan – 3.3%         4,456 Hoya Corp. (Health Care)         517,321           12,851 Kyowa Kirin Co. Ltd. (Health Care)         517,321           940 Lonza Group AG (Health Care)*         514,104           Switzerland – 2.4%         823 Argenx SE ADR (Health Care)         592,390           United Kingdom – 4.1%         5,683 AstraZeneca PLC (Health Care)         592,390           United States – 79.6%         8,033 Abbott Laboratories (Health Care)         1,108,634           6,213 AbbVie, Inc. (Health Care)         1,298,703         958 Align Technology, Inc. (Health Care)*         14,488           9,685 BioMarin Pharmaceuticals, Inc. (Health Care)*         44,488         9,685 BioMarin Pharmaceutical, Inc. (Health Care)*         689,185           1,301 Blueprint Medicines Corp. (Health Care)*         125,637         17,629 Boston Scientific Corp. (Health Care)*         125,637           17,629 Boston Scientific Corp. (Health Care)*         689,185         1,3	Shares	Description	Value
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Common Stoc	ks – 98.5%	
(Health Care)*         \$         142,860           Denmark - 3.8%         9,050         Novo Nordisk A/S, Class B (Health Care)         813,388           France - 0.8%         771         Sartorius Stedim Biotech (Health Care)         159,566           Germany - 1.0%         1,812         BioNTech SE ADR (Health Care)*         204,611           Japan - 3.3%         4,456         Hoya Corp. (Health Care)         517,321           12,851         Kyowa Kirin Co. Ltd. (Health Care)         180,747         698,068           Netherlands - 2.4%         823         Argenx SE ADR (Health Care)*         514,104           Switzerland - 2.8%         940         Lonza Group AG (Health Care)         592,390           United Kingdom - 4.1%         5,683         AstraZeneca PLC (Health Care)         1,298,703           940         Lonza Group AG (Health Care)         1,298,703         958           Maja Abbott Laboratories (Health Care)         1,298,703         958         Align Technology, Inc. (Health Care)*         179,175           1,470         Alnylam Pharmaceuticals, Inc. (Health Care)*         44,488         9,685         80,637           1,301         Blueprint Medicines Corp.         (Health Care)*         125,637           1,7,629         Boston Scientific Corp. (Health Care)*         182,	Canada – 0.7%		
Denmark - 3.8%         9,050         Novo Nordisk A/S, Class B           9,050         Novo Nordisk A/S, Class B         813,388           France - 0.8%         771         Sartorius Stedim Biotech           (Health Care)         159,566           Germany - 1.0%         1,812         BioNTech SE ADR (Health Care)           1,812         BioNTech SE ADR (Health Care)         517,321           12,851         Kyowa Kirin Co. Ltd. (Health Care)         508,068           Netherlands - 2.4%         823         Argenx SE ADR (Health Care)         592,390           940         Lonza Group AG (Health Care)         592,390           United Kingdom - 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States - 79.6%         8,033         Abbott Laboratories (Health Care)         1,08,634           6,213         AbbVie, Inc. (Health Care)         1,298,703         958           9685         BioMarin Pharmaceuticals, Inc.         14,448         179,175           1,470         Alnylam Pharmaceutical, Inc.         689,185         1,301           Blueprint Medicines Corp.         (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc.         689,185           1,301         Blueprint Medicines C	3,859	Xenon Pharmaceuticals, Inc.	
9,050         Novo Nordisk A/S, Class B (Health Care)         813,388           France – 0.8%         771         Sartorius Stedim Biotech (Health Care)         159,566           Germany – 1.0%         1,812         BioNTech SE ADR (Health Care)*         204,611           Japan – 3.3%         4,456         Hoya Corp. (Health Care)         517,321           12,851         Kyowa Kirin Co. Ltd. (Health Care)         180,747           698,068         Netherlands – 2.4%         823           823         Argenx SE ADR (Health Care)*         514,104           Switzerland – 2.8%         940         Lonza Group AG (Health Care)         592,390           United Kingdom – 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States – 79.6%         8,033         Abbott Laboratories (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)*         1,298,703         958           958         BioMarin Pharmaceuticals, Inc. (Health Care)*         44,488         9,685           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         125,637           17,629         Boston Scientific Corp. (Health Care)*         125,637		(Health Care)*	\$ 142,860
9,050         Novo Nordisk A/S, Class B (Health Care)         813,388           France – 0.8%         771         Sartorius Stedim Biotech (Health Care)         159,566           Germany – 1.0%         1,812         BioNTech SE ADR (Health Care)*         204,611           Japan – 3.3%         4,456         Hoya Corp. (Health Care)         517,321           12,851         Kyowa Kirin Co. Ltd. (Health Care)         180,747           698,068         Netherlands – 2.4%         823           823         Argenx SE ADR (Health Care)*         514,104           Switzerland – 2.8%         940         Lonza Group AG (Health Care)         592,390           United Kingdom – 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States – 79.6%         8,033         Abbott Laboratories (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)*         1,298,703         958           958         BioMarin Pharmaceuticals, Inc. (Health Care)*         44,488         9,685           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         125,637           17,629         Boston Scientific Corp. (Health Care)*         125,637	Denmark – 3.8%		
(Health Care)         813,388           France - 0.8%         771         Sartorius Stedim Biotech (Health Care)         159,566           Germany - 1.0%         1,812         BioNTech SE ADR (Health Care)*         204,611           Japan - 3.3%         4,456         Hoya Corp. (Health Care)         517,321           12,851         Kyowa Kirin Co. Ltd. (Health Care)         180,747           698,068         Netherlands - 2.4%         514,104           Switzerland - 2.8%         940         Lonza Group AG (Health Care)         592,390           United Kingdom - 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States - 79.6%         8,033         Abbotic Laboratories (Health Care)         1,108,634           6,213         AbbVie, Inc. (Health Care)         1,298,703         958           958         Align Technology, Inc. (Health Care)*         1,298,703           958         BioMarin Pharmaceuticals, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         1,829,714           4,574         CG oncology, Inc. (Health Care)*         1,829,714           1,629         Boston Scientific Corp. (Health Care)* </td <td></td> <td></td> <td></td>			
771       Sartorius Stedim Biotech (Health Care)       159,566         Germany - 1.0%       1,812       BioNTech SE ADR (Health Care)*       204,611         Japan - 3.3%       4,456       Hoya Corp. (Health Care)       517,321         12,851       Kyowa Kirin Co. Ltd. (Health Care)       180,747       698,068         Netherlands - 2.4%       823       Argenx SE ADR (Health Care)*       514,104         Switzerland - 2.8%       940       Lonza Group AG (Health Care)       592,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       856,401         United States - 79.6%       8,033       Abbott Laboratories (Health Care)       1,108,634         6,213       AbbVie, Inc. (Health Care)       1,298,703       958         958       Align Technology, Inc. (Health Care)*       179,175         1,470       Alnylam Pharmaceuticals, Inc.       (Health Care)*       362,722         1,415       Apogee Therapeutics, Inc.       (Health Care)*       689,185         1,301       Blueprint Medicines Corp.       (Health Care)*       689,185         1,301       Blueprint Medicines Corp.       1,829,714       4,574       CG oncology, Inc. (Health Care)*       18,297,14         4,574       CG oncology, Inc. (The) (Health Care)*       <			813,388
771       Sartorius Stedim Biotech (Health Care)       159,566         Germany - 1.0%       1,812       BioNTech SE ADR (Health Care)*       204,611         Japan - 3.3%       4,456       Hoya Corp. (Health Care)       517,321         12,851       Kyowa Kirin Co. Ltd. (Health Care)       180,747       698,068         Netherlands - 2.4%       823       Argenx SE ADR (Health Care)*       514,104         Switzerland - 2.8%       940       Lonza Group AG (Health Care)       592,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       856,401         United States - 79.6%       8,033       Abbott Laboratories (Health Care)       1,108,634         6,213       AbbVie, Inc. (Health Care)       1,298,703       958         958       Align Technology, Inc. (Health Care)*       179,175         1,470       Alnylam Pharmaceuticals, Inc.       (Health Care)*       362,722         1,415       Apogee Therapeutics, Inc.       (Health Care)*       689,185         1,301       Blueprint Medicines Corp.       (Health Care)*       689,185         1,301       Blueprint Medicines Corp.       1,829,714       4,574       CG oncology, Inc. (Health Care)*       18,297,14         4,574       CG oncology, Inc. (The) (Health Care)*       <			
(Health Care)         159,566           Germany - 1.0%         1,812 BioNTech SE ADR (Health Care)*         204,611           Japan - 3.3%         4,456 Hoya Corp. (Health Care)         517,321           12,851 Kyowa Kirin Co. Ltd. (Health Care)         517,321           12,851 Kyowa Kirin Co. Ltd. (Health Care)         698,068           Netherlands - 2.4%         514,104           Switzerland - 2.8%         940 Lonza Group AG (Health Care)         592,390           United Kingdom - 4.1%         5,683 AstraZeneca PLC (Health Care)         856,401           United States - 79.6%         8,033 Abbott Laboratories (Health Care)         1,298,703           958 Align Technology, Inc. (Health Care)         1,298,703         958 Align Technology, Inc. (Health Care)           1,415 Apogee Therapeutics, Inc. (Health Care)*         362,722         1,415 Apogee Therapeutics, Inc. (Health Care)*         44,488           9,685 BioMarin Pharmaceutical, Inc. (Health Care)*         44,488         9,685 BioMarin Pharmaceutical, Inc. (Health Care)*         125,637           17,629 Boston Scientific Corp. (Health Care)         18,29,714         4,574 CG oncology, Inc. (Health Care)         44,888           9,290 Cooper Cos., Inc. (The) (Health Care)         538,306         3,960 CSL Ltd. (Health Care)         54,306           2,348 Eli Lilly & Co. (Health Care)         538,306 <td< td=""><td></td><td>Sartarius Stadim Diataah</td><td></td></td<>		Sartarius Stadim Diataah	
1,812       BioNTech SE ADR (Health Care)*       204,611         Japan - 3.3%       4,456       Hoya Corp. (Health Care)       517,321         12,851       Kyowa Kirin Co. Ltd. (Health Care)       180,747       698,068         Netherlands - 2.4%       823       Argenx SE ADR (Health Care)*       514,104         Switzerland - 2.8%       940       502,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       592,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       856,401         United States - 79.6%       8       8,033       Abbott Laboratories (Health Care)       1,298,703         958       Align Technology, Inc. (Health Care)       1,298,703       958       Align Technology, Inc. (Health Care)       1,298,703         958       Align Technology, Inc. (Health Care)       1,298,703       958       362,722         1,415       Apogee Therapeutical, Inc. (Health Care)*       362,722       1,415       Apogee Therapeutical, Inc. (Health Care)*       362,722         1,415       Apogee Therapeutical, Inc. (Health Care)*       44,488       9,685       BioMarin Pharmaceutical, Inc. (Health Care)*       125,637         1,629       Boston Scientific Corp. (Health Care)       689,185       1,301       Blueprint Medic	//1		159,566
Care)*         204,611           Japan - 3.3%         4,456         Hoya Corp. (Health Care)         517,321           12,851         Kyowa Kirin Co. Ltd. (Health Care)         180,747         698,068           Netherlands - 2.4%         823         Argenx SE ADR (Health Care)*         514,104           Switzerland - 2.8%         940         Lonza Group AG (Health Care)         592,390           United Kingdom - 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States - 79.6%         8,033         Abbott Laboratories (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)         689,185           1,470         Alnylam Pharmaceutical, Inc. (Health Care)*         162,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         689,185 <td>Germany – 1.0%</td> <td></td> <td></td>	Germany – 1.0%		
Japan - 3.3%       4,456       Hoya Corp. (Health Care)       517,321         12,851       Kyowa Kirin Co. Ltd. (Health Care)       180,747         698,068       698,068         Netherlands - 2.4%       698,068         Switzerland - 2.8%       940       Lonza Group AG (Health Care)*       514,104         Switzerland - 2.8%       940       Lonza Group AG (Health Care)       592,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       856,401         United States - 79.6%       8,033       Abbott Laboratories (Health Care)       1,108,634         6,213       AbbVie, Inc. (Health Care)       1,298,703         958       Align Technology, Inc. (Health Care)       44,488         9,685       BioMarin Pharmaceuticals, Inc. (Health Care)*       44,488         9,685       BioMarin Pharmaceutical, Inc. (Health Care)*       18,29,714         1,574       CG oncology, Inc. (Health Care)       18,29,714         4,574       CG oncology, Inc. (Health Care)       538,306         2,960 <t< td=""><td>1,812</td><td>BioNTech SE ADR (Health</td><td></td></t<>	1,812	BioNTech SE ADR (Health	
4,456       Hoya Corp. (Health Care)       517,321         12,851       Kyowa Kirin Co. Ltd. (Health Care)       180,747         698,068       Netherlands - 2.4%       698,068         Netherlands - 2.4%       823       Argenx SE ADR (Health Care)*       514,104         Switzerland - 2.8%       940       Lonza Group AG (Health Care)       592,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       856,401         United States - 79.6%       8,033       Abbott Laboratories (Health Care)       1,298,703         958       Align Technology, Inc. (Health Care)       44,488         9,685       BioMarin Pharmaceutical, Inc.       (Health Care)*       44,488         9,685       BioMarin Pharmaceutical, Inc.       (Health Care)*       125,637         17,629       Boston Scientific Corp. (Health Care)       689,185         1,301       Blueprint Medicines Corp		Care)*	204,611
4,456       Hoya Corp. (Health Care)       517,321         12,851       Kyowa Kirin Co. Ltd. (Health Care)       180,747         698,068       Retherlands - 2.4%       698,068         Netherlands - 2.4%       514,104         Switzerland - 2.8%       940       Lonza Group AG (Health Care)*       514,104         Switzerland - 2.8%       940       Lonza Group AG (Health Care)       592,390         United Kingdom - 4.1%       5,683       AstraZeneca PLC (Health Care)       856,401         United States - 79.6%       8,033       Abbott Laboratories (Health Care)       1,298,703         958       Align Technology, Inc. (Health Care)       362,722         1,470       Alnylam Pharmaceuticals, Inc. (Health Care)*       44,488         9,685       BioMarin Pharmaceutical, Inc. (Health Care)*       44,488         9,685       BioMarin Pharmaceutical, Inc. (Health Care)*       1,829,714         4,574       CG oncology, Inc. (Health Care)       44,488	Japan – 3.3%		
$\begin{array}{c} 12,851 \ \text{Kyowa Kirin Co. Ltd. (Health} \\ Care) & 180,747 \\ \hline & 698,068 \\ \hline \\ \hline \\ \textbf{Netherlands - 2.4\%} & 514,104 \\ \hline \\ \hline \\ \textbf{Switzerland - 2.8\%} & 940 \ \text{Lonza Group AG (Health Care)} & 514,104 \\ \hline \\ \textbf{Switzerland - 2.8\%} & 940 \ \text{Lonza Group AG (Health Care)} & 592,390 \\ \hline \\ \textbf{United Kingdom - 4.1\%} & 5,683 \ \text{AstraZeneca PLC (Health Care)} & 856,401 \\ \hline \\ \textbf{United States - 79.6\%} & 8,033 \ \text{Abbott Laboratories (Health} & Care) & 1,108,634 \\ \hline \\ \textbf{6,213} \ \text{AbbVie, Inc. (Health Care)} & 1,298,703 \\ 958 \ \text{Align Technology, Inc. (Health} & Care)^* & 179,175 \\ \hline 1,470 \ \text{Alnylam Pharmaceuticals, Inc.} & (Health Care)^* & 362,722 \\ \hline 1,415 \ \text{Apogee Therapeutics, Inc.} & (Health Care)^* & 44,488 \\ 9,685 \ \text{BioMarin Pharmaceutical, Inc.} & (Health Care)^* & 125,637 \\ \hline 1,629 \ \text{Boston Scientific Corp. (Health} & Care)^* & 125,637 \\ \hline 1,629 \ \text{Boston Scientific Corp. (Health} & Care)^* & 18,29,714 \\ \hline 4,574 \ \text{CG oncology, Inc. (Health} & Care)^* & 118,284 \\ 9,290 \ \text{Cooper Cos., Inc. (The) (Health} & Care)^* & 339,630 \\ \hline 3,960 \ \text{CSL Ltd. (Health Care)} & 641,661 \\ 2,591 \ \text{Danaher Corp. (Health Care)} & 538,306 \\ 2,348 \ \text{Eli Lilly & Co. (Health Care)} & 2,161,639 \\ 2,307 \ \text{Exact Sciences Corp. (Health} & Care)^* & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health} & Care)^* & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health} & Care)^* & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health} & Care)^* & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health} & Care)^* & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1,006,038 \\ 2,352 \ \text{Intuitive Surgical, Inc. (Health Care)} & 1$	•	Hoya Corp. (Health Care)	517,321
698,068           Netherlands – 2.4%           823         Argenx SE ADR (Health Care)*         514,104           Switzerland – 2.8%           940         Lonza Group AG (Health Care)         592,390           United Kingdom – 4.1%           5,683         AstraZeneca PLC (Health Care)         856,401           United States – 79.6%           8,033         Abbott Laboratories (Health Care)         1,108,634           6,213         AbbVie, Inc. (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         125,637           1,7629         Boston Scientific Corp. (Health Care)         689,185           1,301	12,851	Kyowa Kirin Co. Ltd. (Health	
Netherlands - 2.4%         514,104           Switzerland - 2.8%         940 Lonza Group AG (Health Care) 592,390           United Kingdom - 4.1%         5,683 AstraZeneca PLC (Health Care) 856,401           United States - 79.6%         8,033 Abbott Laboratories (Health Care) 1,298,703           958 Align Technology, Inc. (Health Care) 1,298,703         958 Align Technology, Inc. (Health Care) 1,298,703           958 Align Technology, Inc. (Health Care) 1,298,703         362,722           1,415 Apogee Therapeuticals, Inc. (Health Care)*         362,722           1,415 Apogee Therapeutics, Inc. (Health Care)*         44,488           9,685 BioMarin Pharmaceutical, Inc. (Health Care)*         689,185           1,301 Blueprint Medicines Corp. (Health Care)*         125,637           17,629 Boston Scientific Corp. (Health Care)         18,29,714           4,574 CG oncology, Inc. (The) (Health Care)         641,661           2,591 Danaher Corp. (Health Care)         538,306           3,960 CSL Ltd. (Health Care)         538,306           2,348 Eli Lilly & Co. (Health Care)         538,306           2,348 Eli Lilly & Co. (Health Care)         2,161,639           2,3695 Insulet Corp. (Health Care)*         1,006,038           2,352 Intuitive Surgical, Inc. (Health         1,006,038		Care)	180,747
823 Argenx SE ADR (Health Care)*514,104Switzerland – 2.8%940 Lonza Group AG (Health Care)592,390United Kingdom – 4.1%5,683 AstraZeneca PLC (Health Care)856,401United States – 79.6%8,033 Abbott Laboratories (Health Care)1,108,6346,213 AbbVie, Inc. (Health Care)1,298,703958 Align Technology, Inc. (Health Care)*179,1751,470 Alnylam Pharmaceuticals, Inc. (Health Care)*362,7221,415 Apogee Therapeutics, Inc. (Health Care)*44,4889,685 BioMarin Pharmaceutical, Inc. (Health Care)*689,1851,301 Blueprint Medicines Corp. (Health Care)*125,63717,629 Boston Scientific Corp. (Health Care)*118,2849,200 Cooper Cos., Inc. (The) (Health Care)*839,6303,960 CSL Ltd. (Health Care)538,3062,348 Eli Lilly & Co. (Health Care)538,3062,348 Eli Lilly & Co. (Health Care)2,161,6392,307 Exact Sciences Corp. (Health Care)*109,3753,695 Insulet Corp. (Health Care)*1,006,0382,352 Intuitive Surgical, Inc. (Health1,006,038			698,068
Switzerland – 2.8%         940         Lonza Group AG (Health Care)         592,390           United Kingdom – 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States – 79.6%         8,033         Abbott Laboratories (Health Care)         1,108,634           6,213         AbbVie, Inc. (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         1,829,714           4,574         CG oncology, Inc. (Health Care)         1,829,714           4,574         CG oncology, Inc. (The) (Health Care)         538,306 <td>Netherlands – 2.</td> <td>4%</td> <td></td>	Netherlands – 2.	4%	
940         Lonza Group AG (Health Care)         592,390           United Kingdom – 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States – 79.6%         8,033         Abbott Laboratories (Health Care)         1,108,634           6,213         AbbVie, Inc. (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         125,637           17,629         Boston Scientific Corp. (Health Care)         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         1,829,714           4,574         CG oncology, Inc. (Health Care)         538,306           2,960         Cooper Cos., Inc. (The) (Health Care)         538,306           2,960	823	Argenx SE ADR (Health Care)*	514,104
940         Lonza Group AG (Health Care)         592,390           United Kingdom – 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States – 79.6%         8,033         Abbott Laboratories (Health Care)         1,108,634           6,213         AbbVie, Inc. (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)         362,722           1,415         Apogee Therapeutics, Inc.         (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc.         (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc.         (Health Care)*         125,637           17,629         Boston Scientific Corp. (Health Care)         1,829,714           4,574         CG oncology, Inc. (Health Care)         641,661           Care)*         118,284         9,290         600 FCL Ltd. (Health	Switzerland – 2.	8%	
United Kingdom - 4.1%         5,683         AstraZeneca PLC (Health Care)         856,401           United States - 79.6%         8,033         Abbott Laboratories (Health Care)         1,108,634           6,213         AbbVie, Inc. (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)         1,298,703           958         Align Technology, Inc. (Health Care)         179,175           1,470         Alnylam Pharmaceuticals, Inc. (Health Care)*         362,722           1,415         Apogee Therapeutics, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         44,488           9,685         BioMarin Pharmaceutical, Inc. (Health Care)*         125,637           17,629         Boston Scientific Corp. (Health Care)*         125,637           17,629         Boston Scientific Corp. (Health Care)*         1,829,714           4,574         CG oncology, Inc. (Health Care)         118,284           9,290         Cooper Cos., Inc. (The) (Health Care)         538,306           2,960         CSL Ltd. (Health Care)         538,306           2,348         Eli Lilly & Co. (Health Care)         2,161,639           2,307         Exact Sciences Corp. (Health Care)         2,161,639           2,307			592.390
5,683       AstraZeneca PLC (Health Care) $856,401$ United States - 79.6%       8,033       Abbott Laboratories (Health Care) $1,108,634$ 6,213       AbbVie, Inc. (Health Care) $1,298,703$ 958       Align Technology, Inc. (Health Care) $362,722$ 1,415       Apogee Therapeutics, Inc. (Health Care) $44,488$ 9,685       BioMarin Pharmaceutical, Inc. (Health Care) $44,488$ 9,685       BioMarin Pharmaceutical, Inc. (Health Care) $125,637$ 17,629       Boston Scientific Corp. (Health Care) $18,29,714$ 4,574       CG oncology, Inc. (Health Care) $18,284$ 9,290       Cooper Cos., Inc. (The) (Health Care) $641,661$ 2,571       Danaher Corp. (Health Care) $538,306$ 2,348       Eli Lilly & Co. (Health Care) $2,161,639$ 2,307<			
United States - 79.6% $8,033$ Abbott Laboratories (Health Care) $1,108,634$ $6,213$ AbbVie, Inc. (Health Care) $1,298,703$ $958$ Align Technology, Inc. (Health Care)* $179,175$ $1,470$ Alnylam Pharmaceuticals, Inc. (Health Care)* $362,722$ $1,415$ Apogee Therapeutics, Inc. (Health Care)* $362,722$ $1,415$ Apogee Therapeutics, Inc. (Health Care)* $44,488$ $9,685$ BioMarin Pharmaceutical, Inc. (Health Care)* $689,185$ $1,301$ Blueprint Medicines Corp. (Health Care)* $125,637$ $17,629$ Boston Scientific Corp. (Health Care)* $18,29,714$ $4,574$ CG oncology, Inc. (Health Care)* $118,284$ $9,290$ Cooper Cos., Inc. (The) (Health Care)* $641,661$ $2,591$ Danaher Corp. (Health Care) $538,306$ $2,307$ Exact Sciences Corp. (Health Care) $2,161,639$ $2,307$ Exact Sciences Corp. (Health Care) $2,161,639$ $2,307$ Exact Sciences Corp. (Health Care) $2,161,639$ $2,305$ Insulet Corp. (Health Care)* $1,006,038$ $2,352$ Intuitive Surgical, Inc. (Health $1,006,038$	-		956 401
8,033 Abbott Laboratories (Health Care) $1,108,634$ $6,213$ AbbVie, Inc. (Health Care) $1,298,703$ $958$ Align Technology, Inc. (Health Care)* $1,298,703$ $958$ Align Technology, Inc. (Health Care)* $179,175$ $1,470$ Alnylam Pharmaceuticals, Inc. (Health Care)* $362,722$ $1,415$ Apogee Therapeutics, Inc. (Health Care)* $44,488$ $9,685$ BioMarin Pharmaceutical, Inc. (Health Care)* $689,185$ $1,301$ Blueprint Medicines Corp. (Health Care)* $125,637$ $17,629$ Boston Scientific Corp. (Health Care)* $1,829,714$ $4,574$ CG oncology, Inc. (Health Care)* $118,284$ $9,290$ Cooper Cos., Inc. (The) (Health Care)* $839,630$ $3,960$ CSL Ltd. (Health Care) $538,306$ $2,348$ Eli Lilly & Co. (Health Care) $538,306$ $2,307$ Exact Sciences Corp. (Health Care)* $109,375$ $3,695$ Insulet Corp. (Health Care)* $1,006,038$ $2,352$ Intuitive Surgical, Inc. (Health $1,006,038$	5,085	Astrazeneca FLC (Health Care)	830,401
Care)       1,108,634 $6,213$ AbbVie, Inc. (Health Care)       1,298,703 $958$ Align Technology, Inc. (Health Care)*       179,175 $1,470$ Alnylam Pharmaceuticals, Inc. (Health Care)*       362,722 $1,415$ Apogee Therapeutics, Inc. (Health Care)*       362,722 $1,415$ Apogee Therapeutics, Inc. (Health Care)*       44,488 $9,685$ BioMarin Pharmaceutical, Inc. (Health Care)*       689,185 $1,301$ Blueprint Medicines Corp. (Health Care)*       125,637 $17,629$ Boston Scientific Corp. (Health Care)*       1,829,714 $4,574$ CG oncology, Inc. (Health Care)       118,284 $9,290$ Cooper Cos., Inc. (The) (Health Care)       641,661 $2,591$ Danaher Corp. (Health Care)       538,306 $2,348$ Eli Lilly & Co. (Health Care)       2,161,639 $2,307$ Exact Sciences Corp. (Health Care)       2,161,639 $2,365$ Insulet Corp. (Health Care)*       1,006,038 $2,352$ Intuitive Surgical, Inc. (Health       1,006,038	United States –	79.6%	
6,213 AbbVie, Inc. (Health Care) $1,298,703$ $958$ Align Technology, Inc. (Health Care)* $179,175$ $1,470$ Alnylam Pharmaceuticals, Inc. (Health Care)* $362,722$ $1,415$ Apogee Therapeutics, Inc. (Health Care)* $44,488$ $9,685$ BioMarin Pharmaceutical, Inc. (Health Care)* $689,185$ $1,301$ Blueprint Medicines Corp. (Health Care)* $125,637$ $17,629$ Boston Scientific Corp. (Health Care)* $18,229,714$ $4,574$ CG oncology, Inc. (Health Care)* $118,284$ $9,290$ Cooper Cos., Inc. (The) (Health Care)* $641,661$ $2,591$ Danaher Corp. (Health Care) $538,306$ $2,307$ Exact Sciences Corp. (Health Care)* $109,375$ $3,695$ Insulet Corp. (Health Care)* $1,006,038$ $2,352$ Intuitive Surgical, Inc. (Health $1,006,038$	8,033	Abbott Laboratories (Health	
958Align Technology, Inc. (Health Care)*179,1751,470Alnylam Pharmaceuticals, Inc. (Health Care)*362,7221,415Apogee Therapeutics, Inc. (Health Care)*44,4889,685BioMarin Pharmaceutical, Inc. (Health Care)*689,1851,301Blueprint Medicines Corp. (Health Care)*125,63717,629Boston Scientific Corp. (Health Care)*1,829,7144,574CG oncology, Inc. (Health Care)*118,2849,290Cooper Cos., Inc. (The) (Health Care)*641,6612,591Danaher Corp. (Health Care)538,3062,348Eli Lilly & Co. (Health Care)2,161,6392,307Exact Sciences Corp. (Health Care)*109,3753,695Insulet Corp. (Health Care)*1,006,0382,352Intuitive Surgical, Inc. (Health1,006,038		· · · · · · · · · · · · · · · · · · ·	· · ·
Care)*179,1751,470Alnylam Pharmaceuticals, Inc. (Health Care)*362,7221,415Apogee Therapeutics, Inc. (Health Care)*44,4889,685BioMarin Pharmaceutical, Inc. (Health Care)*689,1851,301Blueprint Medicines Corp. (Health Care)*125,63717,629Boston Scientific Corp. (Health Care)*1,829,7144,574CG oncology, Inc. (Health Care)*118,2849,290Cooper Cos., Inc. (The) (Health Care)*641,6612,591Danaher Corp. (Health Care)538,3062,348Eli Lilly & Co. (Health Care)2,161,6392,307Exact Sciences Corp. (Health Care)*109,3753,695Insulet Corp. (Health Care)1,006,0382,352Intuitive Surgical, Inc. (Health1,006,038			1,298,703
1,470Alnylam Pharmaceuticals, Inc. (Health Care)* $362,722$ 1,415Apogee Therapeutics, Inc. (Health Care)* $44,488$ 9,685BioMarin Pharmaceutical, Inc. (Health Care)* $689,185$ 1,301Blueprint Medicines Corp. (Health Care)* $125,637$ 17,629Boston Scientific Corp. (Health Care)* $18,29,714$ 4,574CG oncology, Inc. (Health Care)* $118,284$ 9,290Cooper Cos., Inc. (The) (Health Care)* $641,661$ 2,591Danaher Corp. (Health Care) $538,306$ 2,348Eli Lilly & Co. (Health Care) $2,161,639$ 2,307Exact Sciences Corp. (Health Care)* $109,375$ 3,695Insulet Corp. (Health Care)* $1,006,038$ 2,352Intuitive Surgical, Inc. (Health $102,375$	958		170 175
$(Health Care)^*$ $362,722$ $1,415$ Apogee Therapeutics, Inc. (Health Care)* $44,488$ $9,685$ BioMarin Pharmaceutical, Inc. (Health Care)* $689,185$ $1,301$ Blueprint Medicines Corp. (Health Care)* $125,637$ $17,629$ Boston Scientific Corp. (Health Care)* $1,829,714$ $4,574$ CG oncology, Inc. (Health Care)* $118,284$ $9,290$ Cooper Cos., Inc. (The) (Health Care)* $641,661$ $2,591$ Danaher Corp. (Health Care) $538,306$ $2,348$ Eli Lilly & Co. (Health Care) $2,161,639$ $2,307$ Exact Sciences Corp. (Health Care)* $109,375$ $3,695$ Insulet Corp. (Health Care)* $1,006,038$ $2,352$ Intuitive Surgical, Inc. (Health $109,375$	1 470	,	1/9,1/5
1,415Apogee Therapeutics, Inc. (Health Care)*44,4889,685BioMarin Pharmaceutical, Inc. (Health Care)*689,1851,301Blueprint Medicines Corp. (Health Care)*125,63717,629Boston Scientific Corp. (Health Care)*1,829,7144,574CG oncology, Inc. (Health Care)*118,2849,290Cooper Cos., Inc. (The) (Health Care)*641,6612,591Danaher Corp. (Health Care)538,3062,348Eli Lilly & Co. (Health Care)2,161,6392,307Exact Sciences Corp. (Health Care)*109,3753,695Insulet Corp. (Health Care)1,006,0382,352Intuitive Surgical, Inc. (Health1,006,038	1,470		362,722
(Health Care)* $44,488$ 9,685       BioMarin Pharmaceutical, Inc.         (Health Care)* $689,185$ 1,301       Blueprint Medicines Corp.         (Health Care)* $125,637$ 17,629       Boston Scientific Corp. (Health         Care)* $1,829,714$ 4,574       CG oncology, Inc. (Health         Care)* $118,284$ 9,290       Cooper Cos., Inc. (The) (Health         Care)* $839,630$ 3,960       CSL Ltd. (Health Care)         641,661 $2,591$ Danaher Corp. (Health Care) $538,306$ 2,348       Eli Lilly & Co. (Health Care) $2,161,639$ 2,307       Exact Sciences Corp. (Health Care) $2,161,639$ 2,307       Exact Sciences Corp. (Health Care) $1,006,038$ 2,352       Intuitive Surgical, Inc. (Health $1,006,038$	1,415		,
$(\text{Health Care})^* \qquad 689,185$ 1,301 Blueprint Medicines Corp. (Health Care)* 125,637 17,629 Boston Scientific Corp. (Health Care)* 1,829,714 4,574 CG oncology, Inc. (Health Care)* 118,284 9,290 Cooper Cos., Inc. (The) (Health Care)* 839,630 3,960 CSL Ltd. (Health Care) 641,661 2,591 Danaher Corp. (Health Care) 538,306 2,348 Eli Lilly & Co. (Health Care) 2,161,639 2,307 Exact Sciences Corp. (Health Care)* 109,375 3,695 Insulet Corp. (Health Care)* 1,006,038 2,352 Intuitive Surgical, Inc. (Health		(Health Care)*	44,488
$\begin{array}{cccc} 1,301 & \text{Blueprint Medicines Corp.} \\ & (\text{Health Care})^{*} & 125,637 \\ \hline 17,629 & \text{Boston Scientific Corp. (Health} \\ & & \text{Care})^{*} & 1,829,714 \\ \hline 4,574 & \text{CG oncology, Inc. (Health} \\ & & \text{Care})^{*} & 118,284 \\ \hline 9,290 & \text{Cooper Cos., Inc. (The) (Health} \\ & & \text{Care})^{*} & 839,630 \\ \hline 3,960 & \text{CSL Ltd. (Health Care}) & 641,661 \\ \hline 2,591 & \text{Danaher Corp. (Health Care)} & 538,306 \\ \hline 2,348 & \text{Eli Lilly & Co. (Health Care)} & 2,161,639 \\ \hline 2,307 & \text{Exact Sciences Corp. (Health} \\ & & \text{Care})^{*} & 109,375 \\ \hline 3,695 & \text{Insulet Corp. (Health Care)} & 1,006,038 \\ \hline 2,352 & \text{Intuitive Surgical, Inc. (Health} \\ \hline \end{array}$	9,685		
$\begin{array}{ccccc} (Health Care)^* & 125,637\\ 17,629 & Boston Scientific Corp. (Health Care)^* & 1,829,714\\ 4,574 & CG oncology, Inc. (Health Care)^* & 118,284\\ 9,290 & Cooper Cos., Inc. (The) (Health Care)^* & 839,630\\ 3,960 & CSL Ltd. (Health Care) & 641,661\\ 2,591 & Danaher Corp. (Health Care) & 538,306\\ 2,348 & Eli Lilly & Co. (Health Care) & 2,161,639\\ 2,307 & Exact Sciences Corp. (Health Care)^* & 109,375\\ 3,695 & Insulet Corp. (Health Care)^* & 1,006,038\\ 2,352 & Intuitive Surgical, Inc. (Health \\ \end{array}$	1 201		689,185
17,629Boston Scientific Corp. (Health Care)* $1,829,714$ $4,574$ CG oncology, Inc. (Health Care)* $118,284$ $9,290$ Cooper Cos., Inc. (The) (Health Care)* $839,630$ $3,960$ CSL Ltd. (Health Care) $641,661$ $2,591$ Danaher Corp. (Health Care) $538,306$ $2,348$ Eli Lilly & Co. (Health Care) $2,161,639$ $2,307$ Exact Sciences Corp. (Health Care)* $109,375$ $3,695$ Insulet Corp. (Health Care)* $1,006,038$ $2,352$ Intuitive Surgical, Inc. (Health	1,301		125 627
$\begin{array}{c} {\rm Care} )^{*} & 1,829,714 \\ 4,574 \ {\rm CG} \ {\rm oncology,  Inc.  (Health \ {\rm Care})^{*}} & 118,284 \\ 9,290 \ {\rm Cooper  Cos.,  Inc.  (The)  (Health \ {\rm Care})^{*}} & 839,630 \\ 3,960 \ {\rm CSL  Ltd.  (Health  {\rm Care})} & 641,661 \\ 2,591 \ {\rm Danaher  Corp.  (Health  {\rm Care})} & 538,306 \\ 2,348 \ {\rm Eli  Lilly  \&  Co.  (Health  {\rm Care})} & 2,161,639 \\ 2,307 \ {\rm Exact  Sciences  Corp.  (Health \ {\rm Care})^{*}} & 109,375 \\ 3,695 \ {\rm Insulet  Corp.  (Health  {\rm Care})^{*}} & 1,006,038 \\ 2,352 \ {\rm Intuitive  Surgical,  Inc.  (Health  {\rm Care})^{*}} \end{array}$	17 629	· /	125,057
4,574 CG oncology, Inc. (Health Care)*       118,284 $9,290$ Cooper Cos., Inc. (The) (Health Care)*       839,630 $3,960$ CSL Ltd. (Health Care)       641,661 $2,591$ Danaher Corp. (Health Care)       538,306 $2,348$ Eli Lilly & Co. (Health Care)       2,161,639 $2,307$ Exact Sciences Corp. (Health Care)*       109,375 $3,695$ Insulet Corp. (Health Care)*       1,006,038 $2,352$ Intuitive Surgical, Inc. (Health       109,375	17,029	÷ .	1.829.714
9,290       Cooper Cos., Inc. (The) (Health Care)*       839,630         3,960       CSL Ltd. (Health Care)       641,661         2,591       Danaher Corp. (Health Care)       538,306         2,348       Eli Lilly & Co. (Health Care)       2,161,639         2,307       Exact Sciences Corp. (Health Care)*       109,375         3,695       Insulet Corp. (Health Care)*       1,006,038         2,352       Intuitive Surgical, Inc. (Health       109,375	4,574		-,-=>,,11
Care)*         839,630           3,960         CSL Ltd. (Health Care)         641,661           2,591         Danaher Corp. (Health Care)         538,306           2,348         Eli Lilly & Co. (Health Care)         2,161,639           2,307         Exact Sciences Corp. (Health Care)*         109,375           3,695         Insulet Corp. (Health Care)*         1,006,038           2,352         Intuitive Surgical, Inc. (Health         1,006,038	ŕ	Care)*	118,284
3,960       CSL Ltd. (Health Care)       641,661         2,591       Danaher Corp. (Health Care)       538,306         2,348       Eli Lilly & Co. (Health Care)       2,161,639         2,307       Exact Sciences Corp. (Health Care)       2,307         3,695       Insulet Corp. (Health Care)*       1,006,038         2,352       Intuitive Surgical, Inc. (Health       1,006,038	9,290		
2,591       Danaher Corp. (Health Care)       538,306         2,348       Eli Lilly & Co. (Health Care)       2,161,639         2,307       Exact Sciences Corp. (Health Care)*       109,375         3,695       Insulet Corp. (Health Care)*       1,006,038         2,352       Intuitive Surgical, Inc. (Health       1,006,038	2.0.40		
2,348       Eli Lilly & Co. (Health Care)       2,161,639         2,307       Exact Sciences Corp. (Health Care)*       109,375         3,695       Insulet Corp. (Health Care)*       1,006,038         2,352       Intuitive Surgical, Inc. (Health       109,375			
2,307Exact Sciences Corp. (Health Care)*109,3753,695Insulet Corp. (Health Care)*1,006,0382,352Intuitive Surgical, Inc. (Health1,006,038			,
Care)*         109,375           3,695         Insulet Corp. (Health Care)*         1,006,038           2,352         Intuitive Surgical, Inc. (Health         1			2,101,039
3,695Insulet Corp. (Health Care)*1,006,0382,352Intuitive Surgical, Inc. (Health	2,507		109 375
2,352 Intuitive Surgical, Inc. (Health	3.695	,	
			.,,
		<b>e</b>	1,348,049

Shares	Description	Value
Common Stock	cs – (continued)	
United States – (	(continued)	
2,233	iRhythm Technologies, Inc.	
	(Health Care)*	\$ 245,987
515	Madrigal Pharmaceuticals, Inc.	
	(Health Care)*	175,754
	Merck & Co., Inc. (Health Care)	820,010
222	Mettler-Toledo International,	
	Inc. (Health Care)*	282,544
2,655	MoonLake Immunotherapeutics	
	(Health Care)*	110,873
618	Natera, Inc. (Health Care)*	96,155
3,965	Neurocrine Biosciences, Inc.	
	(Health Care)*	470,725
12,584	Roivant Sciences Ltd. (Health	
	Care)*	135,152
3,490	Ultragenyx Pharmaceutical, Inc.	
	(Health Care)*	149,791
2,212	UnitedHealth Group, Inc.	
	(Health Care)	1,050,611
	Vaxcyte, Inc. (Health Care)*	117,051
2,147	Veeva Systems, Inc., Class A	
	(Health Care)*	481,229
1,251	West Pharmaceutical Services,	
	Inc. (Health Care)	290,657
		16,827,779
TOTAL COMMO	ON STOCKS	
(Cost \$18,752,	298)	20,809,167
Shares	Dividend Rate	Value
Investment Co	mpany – 2.7% <sup>(a)</sup>	
Goldman Sach	s Financial Square Treasury	
Obligations	Fund – Institutional Shares	
577,206	4.253%	577,206
(Cost \$577,200	6)	,

TOTAL INVESTMENTS – 101.2%	
(Cost \$19,329,504)	\$ 21,386,373
LIABILITIES IN EXCESS OF OTHER ASSETS	
– (1.2)%	(249,488)
NET ASSETS – 100.0%	\$ 21,136,885

The percentage shown for each investment category reflects the value of investments in that category as a percentage of net assets.

\* Non-income producing security.

(a) Represents an affiliated issuer.

Investment Abbreviations:	
ADR	-American Depositary Receipt
PLC	-Public Limited Company

4

Sector Name	% of Market Value	
Health Care	97.3%	
Investment Company	2.7	
TOTAL INVESTMENTS	100.0%	

February 28, 2025 (Unaudited)

Shares	Description	Value
Common Stoc	ks – 98.6%	
China – 4.7%		
14,842	BYD Co. Ltd., Class A (Consumer Discretionary) Contemporary Amperex	\$ 736,386
51,957	Technology Co. Ltd., Class A (Industrials)	1,158,201
		1,894,587
Denmark – 4.4%		
	Novonesis (Novozymes) B, Class B (Materials) Vestas Wind Systems A/S	1,554,739
15,088	(Industrials)*	213,351
	(industrials)	1,768,090
France – 3.9%		,,
	Dassault Systemes (Information Technology)	1,106,334
13,817	Imerys SA (Materials)	447,759
,		1,554,093
Germany – 3.2%		
35,006	Infineon Technologies AG (Information Technology)	1,292,786
Ireland – 1.8%		
	Kingspan Group PLC	
	(Industrials)	734,318
Italy – 4.3%		
-	Enel SpA (Utilities)	1,740,630
Japan – 6.9%		
•	Horiba Ltd. (Information	
	Technology) Keyence Corp. (Information	545,523
	Technology) Kurita Water Industries Ltd.	953,272
,	(Industrials)	817,015
24,302	NIDEC Corp. (Industrials)	432,919
		2,748,729
Jersey – 1.4%		
8,549	Aptiv PLC (Consumer Discretionary)*	556,711
Spain – 5.2%		
144,740	Iberdrola SA (Utilities)	2,099,889
Sweden – –%		
18,262	Re:NewCell AB (Materials)*(a)(b)	_
Switzerland – 7.	8%	
	ABB Ltd. (Industrials)	774,566
	DSM-Firmenich AG (Materials)	1,605,087
	SIG Group AG (Materials)*	402,162
1,376	Sika AG (Materials)	348,785
		3,130,600

Shares	Description		Value
Common Stoc	ks – (continued)		
Taiwan – 2.6%			
86,252	Delta Electronics, Inc.		
	(Information Technology)	\$	1,056,710
United States –	52.4%		
2,744	Advanced Drainage Systems,		
,	Inc. (Industrials)		305,654
10,967	AECOM (Industrials)		1,097,248
	Albemarle Corp. (Materials)		225,236
14,097	Ball Corp. (Materials)		742,771
	Bloom Energy Corp., Class A		
	(Industrials)*		825,736
19,717	Darling Ingredients, Inc.		, i i i i i i i i i i i i i i i i i i i
	(Consumer Staples)*		711,587
15,665	DocuSign, Inc. (Information		, i i i i i i i i i i i i i i i i i i i
,	Technology)*		1,302,858
2,722	Eaton Corp. PLC (Industrials)		798,417
2,093	Ecolab, Inc. (Materials)		563,038
	Energy Recovery, Inc.		, i i i i i i i i i i i i i i i i i i i
,	(Industrials)*		341,342
23,853	International Paper Co.		, , , , , , , , , , , , , , , , , , ,
,	(Materials)		1,314,010
9,783	Itron, Inc. (Information		
,	Technology)*		1,065,271
25,728	NextEra Energy, Inc. (Utilities)		1,805,334
	Schneider Electric SE		, ,
	(Industrials)		1,366,905
26,720	Smurfit WestRock PLC		
	(Materials)		1,391,310
16,341	Tetra Tech, Inc. (Industrials)		476,994
2,236	TopBuild Corp. (Consumer		
	Discretionary)*		685,088
2,981	Trane Technologies PLC		
	(Industrials)		1,054,380
5,411	Veralto Corp. (Industrials)		539,801
6,329	Waste Connections, Inc.		
	(Industrials)		1,200,991
9,669	Waste Management, Inc.		
	(Industrials)		2,250,750
7,408	Xylem, Inc. (Industrials)		969,633
			21,034,354
	MENTS BEFORE SECURITIES		
			20 (11 407
(Cost \$44,009,	,857)	_	39,611,497

6

Shares	Dividend Rate		Value
Securities Lending R	einvestment Vehicle –	• <b>0.0%</b> <sup>(c)</sup>	
Goldman Sachs Fina Fund - Institution	ncial Square Governme al Shares	ent	
8,320 (Cost \$8,320)	4.287%	\$	8,320
TOTAL INVESTMENTS (Cost \$44,018,177)	5 - 98.6%		
OTHER ASSETS IN EX	CESS OF LIABILITIES	\$	39,619,817
- 1.4%			561,078
NET ASSETS – 100.0	%	\$	40,180,895

The percentage shown for each investment category reflects the value of investments in that category as a percentage of net assets.

\* Non-income producing security.

(a) All or a portion of security is on loan.

(b) Significant unobservable inputs were used in the valuation of this portfolio security; i.e. Level 3.

(c) Represents an affiliated issuer.

#### Investment Abbreviations:

PLC —Public Limited Company

Sector Name	% of Market Value
Industrials	38.7%
Materials	21.7
Information Technology	18.5
Utilities	14.3
Consumer Discretionary	5.0
Consumer Staples	1.8
Securities Lending Reinvestment Vehicle	0.0
TOTAL INVESTMENTS	100.0%

February 28, 2025 (Unaudited)

Shares	Shares Description							
Common Stoc	ks – 98.4%							
Communication	Services – 10.0%							
	Capcom Co. Ltd. (Japan)	\$ 1,533,031						
	Cellnex Telecom SA (Spain)*(a)	2,123,591						
	NetEase, Inc. (China)	2,282,138						
	Snap, Inc., Class A*	2,770,698						
	Spotify Technology SA* Tencent Music Entertainment	4,315,047						
100,854	Group ADR (China)	1,302,550						
29,187	Trade Desk, Inc. (The), Class A*	2,052,430						
,		16,379,485						
Consumer Discre	tionary – 7.6%	- ) )						
	BYD Co. Ltd., Class H (China)	3,437,987						
	DoorDash, Inc., Class A*	2,378,105						
	MercadoLibre, Inc. (Brazil)*	2,414,688						
	Trip.com Group Ltd. (China)*	2,217,332						
826,203	Zomato Ltd. (India)*	2,097,049						
		12,545,161						
Financials – 2.8%	6							
45,339	Fidelity National Information							
	Services, Inc.	3,224,509						
7,811	Jack Henry & Associates, Inc.	1,355,911						
		4,580,420						
Health Care – 1.								
14,031	Hoya Corp. (Japan)	1,628,935						
Industrials – 2.6	%							
	Daifuku Co. Ltd. (Japan)	3,326,522						
53,827	Ebara Corp. (Japan)	883,692						
		4,210,214						
Information Tech								
73,332	Accton Technology Corp.							
25.000	(Taiwan)	1,504,074						
	Advantest Corp. (Japan) Amphenol Corp., Class A	1,933,794 3,760,236						
	AppLovin Corp., Class A*	1,137,810						
	ASM International NV	1,157,010						
- ,	(Netherlands)	1,844,565						
110,743	ASMPT Ltd. (Hong Kong)	862,988						
	Atlassian Corp., Class A*	4,837,821						
16,428	Cadence Design Systems, Inc.*	4,115,214						
	Chroma ATE, Inc. (Taiwan)	1,759,182						
	Cloudflare, Inc., Class A*	1,564,155						
	Coforge Ltd. (India) Cognizant Technology Solutions	1,686,744						
27,007	Corp., Class A	2,300,491						
6,244	Crowdstrike Holdings, Inc.,	2,500,471						
-,	Class A*	2,433,037						
	Datadog, Inc., Class A*	3,901,744						
	Delta Electronics, Inc. (Taiwan)	2,921,206						
	Dynatrace, Inc.*	4,179,136						
	E Ink Holdings, Inc. (Taiwan)	2,183,371						
	Elastic NV*	1,964,040						
	Entegris, Inc. Hamamatsu Photonics KK	2,360,653						
205,801	(Japan)	2,107,050						
5,951	HubSpot, Inc.*	4,308,464						
- ,- = =	1 /	···· · · · ·						

Shares	Description		Value
Common Stoc	ks – (continued)		
Information Tech	nnology – (continued)		
406,596	JCET Group Co. Ltd., Class A		
	(China)	\$	2,079,103
68,144	Jentech Precision Industrial Co.		
	Ltd. (Taiwan)		2,782,871
	Juniper Networks, Inc.		1,773,402
495,094	King Yuan Electronics Co. Ltd.		
	(Taiwan)		1,622,022
· · · · ·	KLA Corp.		2,829,689
	Klaviyo, Inc., Class A*		2,182,732
· · · · ·	Marvell Technology, Inc.		3,586,673
	MediaTek, Inc. (Taiwan)		4,222,239
	Microchip Technology, Inc.		1,397,101
	Micron Technology, Inc.		2,472,300
· · · · ·	Monday.com Ltd.*		3,632,762
	MongoDB, Inc.*		2,598,617
	Motorola Solutions, Inc.		4,043,421
106,887	Murata Manufacturing Co. Ltd.		1 000 052
14 5 1 1	(Japan)		1,809,053
· · · · ·	Onto Innovation, Inc.*		2,113,672
	Persistent Systems Ltd. (India)		1,406,473
· · · · ·	Samsara, Inc., Class A*		3,471,676
	Shopify, Inc., Class A (Canada)*		2,426,592
· · · · ·	Silergy Corp. (China) SK Hynix, Inc. (South Korea)		1,574,859
	Snowflake, Inc., Class A*		3,227,640 4,869,365
	Tokyo Seimitsu Co. Ltd. (Japan)		1,650,284
	Tyler Technologies, Inc.*		3,966,355
	Varonis Systems, Inc.*		1,780,935
	Venustech Group, Inc., Class A		1,780,955
404,474	(China)		1,082,120
20 357	Zscaler, Inc.*		3,994,654
20,557	Esculei, me.		
TOTAL COMMO			122,262,385
			1(1(0)(00)
<u>(Cost \$141,854</u>			161,606,600
Shares	Dividend Rate		Value
Investment Co	mpany – 1.4% <sup>(b)</sup>		
Goldman Sach	s Financial Square Treasury		
	Fund – Institutional Shares		
2,335,596	4.253%		2,335,596
(Cost \$2,335,5			_,,
	MENTS – 99.8%		
(Cost \$144,19)		¢	162 042 106
-	-	\$	163,942,196
	IN EXCESS OF LIABILITIES		
- 0.2%			382,702
NET ASSETS –	100.0%	\$	164,324,898

The percentage shown for each investment category reflects the value of investments in that category as a percentage of net assets.

8

- \* Non-income producing security.(a) Exempt from registration under Rule 144A of the Securities Act of 1933.
- (b) Represents an affiliated issuer.

Investment Abbreviations: ADR -American Depositary Receipt

# Statements of Assets and Liabilities

February 28, 2025 (Unaudited)

		re Consumer quity ETF	Fu	uture Health Care Equity ETF	Future Planet Equity ETF	Future Tech Leaders Equity ETF		
Assets:								
Investments in unaffiliated issuers, at value (cost \$29,686,376, \$18,752,298, \$44,009,857 and \$141,854,643, respectively) Investments in affiliated issuers, at value (cost \$401,970, \$577,206,	\$	35,080,208	\$	20,809,167	\$ 39,611,497	\$	161,606,600	
S- and \$2,335,596, respectively) Investments in affiliated securities lending reinvestment vehicle, at		401,970		577,206	_		2,335,59	
value which equals cost Foreign Currency, at value (cost \$30,875, \$418, \$- and \$-,		_		—	8,320		-	
respectively)		30,922		419	_		-	
Receivables:		,						
Investments sold		150,928		93,456	1,643,284		1,993,11	
Dividends		15,037		17,615	53,907		63,18	
Foreign tax reclaims		10,947		2,241	90,924		12,93	
Securities lending income		_		—	118		-	
Total assets		35,690,012		21,500,104	41,408,050		166,011,43	
Liabilities:								
Unrealized loss on forward foreign currency exchange contracts Payables:		—		1,597	192		-	
Due to custodian		53,888		93,456	907,888		_	
Management fees		8,223		4,733	9,266		38,70	
Payable upon return of securities loaned					8,320		50,70	
Investments purchased		_		263,433	285,647		1,380,63	
Foreign bank overdraft (cost \$-, \$-, \$15,905 and \$219,								
respectively)		—		—	15,842		21	
Foreign capital gains taxes					_		266,98	
Total liabilities		62,111		363,219	 1,227,155		1,686,53	
Net Assets:								
Paid-in capital		41,827,511		36,433,403	67,503,680		252,321,57	
Total distributable loss		(6,199,610)		(15,296,518)	(27,322,785)		(87,996,67	
NET ASSETS	\$	35,627,901	\$	21,136,885	\$ 40,180,895	\$	164,324,89	
SHARES ISSUED AND OUTSTANDING								
Shares outstanding no par value (unlimited shares authorized):		1,000,000		625,000	1,275,000		5,000,00	
Net asset value per share:	\$	35.63	\$	33.82	\$ 31.51	\$	32.8	

# Statements of Operations

For the Six Months Ended February 28, 2025 (Unaudited)

	F	uture Consumer Equity ETF	Fu	uture Health Care Equity ETF	Future Planet Equity ETF	Fut	ure Tech Leaders Equity ETF
Investment income:							
Dividends — unaffiliated issuers (net of foreign withholding taxes of \$5,114, \$438, \$14,997 and \$38,463, respectively)	\$	133,642	\$	77,341	\$ 274,478	\$	385,160
Dividends — affiliated issuers		21,907		9,651	11,777		65,984
Securities lending income, net of rebates received or paid to borrowers - unaffiliated issuer	-	443		12	1,736		768
Total Investment Income		155,992		87,004	287,991		451,912
Expenses:							
Management fees		164,444		67,820	141,681		620,148
Trustee fees		13,824		13,740	13,807		14,223
Total expenses		178,268		81,560	155,488		634,371
Less — expense reductions		(832)		(387)	(468)		(2,625)
Net expenses		177,436		81,173	155,020		631,746
NET INVESTMENT INCOME (LOSS)		(21,444)		5,831	132,971		(179,834)
Realized and Unrealized gain (loss):							
Net realized gain (loss) from:							
Investments — unaffiliated issuers		(991,114)		(964,396)	(3,310,346)		13,008,854
In-kind redemptions		5,359,530		125,576	173,997		5,894,259
Foreign currency transactions		(6,347)		5,829	(1,892)		(21,824)
Net change in unrealized gain (loss) on:							
Investments — unaffiliated issuers (including the effects of the net change in foreign capital gains tax liability of \$-, \$-, \$- and \$266,983, respectively)		(300,993)		(1,399,041)	2,323,251		(2,748,840)
Foreign currency translations		(1,049)		(179)	(7,315)		(1,200)
Net realized and unrealized gain (loss)		4,060,027		(2,232,211)	(822,305)		16,131,249
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS	\$	4,038,583	\$	(2,226,380)	\$ (689,334)	\$	15,951,415

11

# Statements of Changes in Net Assets

	_	Future Cor	isume	r Equity ETF	_	Future Health Care Equity ETF				
	_	For the Six Months Ended February 28, 2025 (Unaudited)		For the Fiscal Year Ended August 31, 2024	_	For the Six Months Ended February 28, 2025 (Unaudited)		For the Fiscal Year Ended August 31, 2024		
From operations:										
Net investment income (loss)	\$	(21,444)	\$	69,761	\$	5,831	\$	7,556		
Net realized gain (loss)		4,362,069		1,931,952		(832,991)		(10,242,215)		
Net change in unrealized gain (loss)		(302,042)		12,002,662		(1,399,220)		3,438,997		
Net increase (decrease) in net assets resulting from operations		4,038,583		14,004,375		(2,226,380)		(6,795,662)		
Distributions to shareholders:										
From distributable earnings		(468,540)		(364,636)		(3,600)		(134,205)		
From share transactions:										
Proceeds from sales of shares		-		20,844,686		-		-		
Cost of shares redeemed		(29,939,770)		(128,695,327)		(827,726)		(80,716,187		
Net decrease in net assets resulting from share transactions		(29,939,770)		(107,850,641)		(827,726)		(80,716,187		
TOTAL DECREASE		(26,369,727)		(94,210,902)		(3,057,706)		(87,646,054		
Net Assets:										
Beginning of period	\$	61,997,628	\$	156,208,530	\$	24,194,591	\$	111,840,645		
End of period	\$	35,627,901	\$	61,997,628	\$	21,136,885	\$	24,194,591		

# Statements of Changes in Net Assets (continued)

		Future P	anet	Equity ETF		Future Tech Leaders Equity ETF				
	_	For the Six Months Ended February 28, 2025 (Unaudited)		For the Fiscal Year Ended August 31, 2024	_	For the Six Months Ended February 28, 2025 (Unaudited)		For the Fiscal Year Ended August 31, 2024		
From operations:										
Net investment income (loss)	\$	132,971	\$	662,932	\$	(179,834)	\$	(63,486)		
Net realized gain (loss)		(3,138,241)		(33,642,828)		18,881,289		(22,519,446)		
Net change in unrealized gain (loss)		2,315,936		27,424,545		(2,750,040)		47,247,625		
Net increase (decrease) in net assets resulting from operations		(689,334)		(5,555,351)		15,951,415		24,664,693		
Distributions to shareholders:										
From distributable earnings		(434,161)		(1,539,345)		-		(431,486)		
From share transactions:										
Proceeds from sales of shares		_		_		2,674,565		12,937,052		
Cost of shares redeemed		(2,409,005)		(91,661,802)		(29,875,904)		(117,490,811)		
Net decrease in net assets resulting from share transactions		(2,409,005)		(91,661,802)		(27,201,339)		(104,553,759		
TOTAL DECREASE		(3,532,500)		(98,756,498)		(11,249,924)		(80,320,552)		
Net Assets:										
Beginning of period	\$	43,713,395	\$	142,469,893	\$	175,574,822	\$	255,895,374		
End of period	\$	40,180,895	\$	43,713,395	\$	164,324,898	\$	175,574,822		

# **Financial Highlights**

Selected Data for a Share Outstanding Throughout Each Period

		Future Consum	er Equi	ity ETF				
	 he Six Months Ended	For the Year Ended		31,	For the Period November 9, 2021*			
	uary 28, 2025 Jnaudited)	2024	2023		Augi	to ıst 31, 2022		
Per Share Operating Performance:								
Net asset value, beginning of period	\$ 33.51	\$ 27.17	\$	25.43	\$	40.03		
Net investment income (loss) <sup>(a)</sup>	(0.02)	0.02		0.08		0.10		
Net realized and unrealized gain (loss)	2.61	6.45		1.66		(14.62)		
Total from investment operations	2.59	6.47		1.74		(14.52)		
Distributions to shareholders from net investment income	(0.47)	(0.13)		_		(0.06)		
Distributions to shareholders from return of capital	-	_		-		(0.02)		
Total distributions	(0.47)	(0.13)		_		(0.08)		
Net asset value, end of period	\$ 35.63	\$ 33.51	\$	27.17	\$	25.43		
Market price, end of period	\$ 35.44	\$ 33.47	\$	27.20	\$	25.30		
Total Return at Net Asset Value <sup>(b)</sup>	7.71%	23.89%		6.84%	Ď	(36.28)%		
Net assets, end of period (in 000's)	\$ 35,628	\$ 61,998	\$	156,209	\$	89,001		
Ratio of net expenses to average net assets	0.75% <sup>(c)</sup>	0.75%		0.75%	, D	0.75% <sup>(c)</sup>		
Ratio of net investment income (loss) to average net assets	(0.09)% <sup>(c)</sup>	0.08%		0.32%	, D	0.46% <sup>(c)</sup>		
Portfolio turnover rate <sup>(d)</sup>	26%	31%		16%	, D	24%		

\* Commencement of operations.

<sup>(a)</sup> Calculated based on the average shares outstanding methodology.

(b) Assumes investment at the net asset value at the beginning of the period, reinvestment of all distributions and a complete sale of the investment at the net asset value at the beginning of the period, reinvestment of all distributions or the sale of Fund shares. Total returns for periods less than one full year are not annualized.

(c) Annualized.

<sup>(d)</sup> The Fund's portfolio turnover rate is calculated in accordance with regulatory requirements and excludes portfolio securities received or delivered as a result of in-kind transactions and short-term transactions. If such transactions were included, the Fund's portfolio turnover rate may be higher.

# Financial Highlights (continued)

Selected Data for a Share Outstanding Throughout Each Period

		Future Health Care Equity ETF								
	For the Six Months Ended			For the I Year Ended A	: 31,		For the Period ovember 9, 2021*			
		ary 28, 2025 naudited)	2024			2023	Aug	to just 31, 2022		
Per Share Operating Performance:										
Net asset value, beginning of period	\$	37.22	\$	32.42	\$	29.94	\$	39.68		
Net investment income (loss) <sup>(a)</sup>		0.01		0.01		(0.04)		(0.08)		
Net realized and unrealized gain (loss)		(3.40)		4.97		2.52		(9.66)		
Total from investment operations		(3.39)		4.98		2.48		(9.74)		
Distributions to shareholders from net investment income		(0.01)		(0.18)		_(b)		_		
Net asset value, end of period	\$	33.82	\$	37.22	\$	32.42	\$	29.94		
Market price, end of period	\$	33.88	\$	37.23	\$	32.42	\$	30.00		
Total Return at Net Asset Value <sup>(c)</sup>		(9.12)%		15.44%		8.28%		(24.55)%		
Net assets, end of period (in 000's)	\$	21,137	\$	24,195	\$	111,841	\$	101,781		
Ratio of net expenses to average net assets		0.75% <sup>(d)</sup>		0.75%		0.75%		0.75% <sup>(d)</sup>		
Ratio of net investment income (loss) to average net assets		0.05% <sup>(d)</sup>		0.02%		(0.14)%		(0.33)% <sup>(d)</sup>		
Portfolio turnover rate <sup>(e)</sup>		24%		45%		28%		24%		

\* Commencement of operations.

<sup>(a)</sup> Calculated based on the average shares outstanding methodology.

<sup>(b)</sup> Amount is less than \$0.005 per share.

(c) Assumes investment at the net asset value at the beginning of the period, reinvestment of all distributions and a complete sale of the investment at the net asset value at the end of the period. Returns do not reflect the impact of taxes to shareholders relating to Fund distributions or the sale of Fund shares. Total returns for periods less than one full year are not annualized.

(d) Annualized.

(e) The Fund's portfolio turnover rate is calculated in accordance with regulatory requirements and excludes portfolio securities received or delivered as a result of in-kind transactions and short-term transactions. If such transactions were included, the Fund's portfolio turnover rate may be higher.

# Financial Highlights (continued)

Selected Data for a Share Outstanding Throughout Each Period

			Fu	ture P	lanet Equity ETF				
		ne Six Months Ended	Y			or the Period Ily 13, 2021*			
		uary 28, 2025 Inaudited)	2024		2023		2022	to August 31, 2021	
Per Share Operating Performance:									
Net asset value, beginning of period	\$	32.38	\$ 30.15	\$	30.23	\$	42.18	\$	39.89
Net investment income <sup>(a)</sup>		0.10	0.32		0.30		0.27		0.02
Net realized and unrealized gain (loss)		(0.64)	2.94		(0.27)		(12.05)		2.27
Total from investment operations		(0.54)	3.26		0.03		(11.78)		2.29
Distributions to shareholders from net investment									
income		(0.33)	(1.03)		(0.11)		(0.17)		_
Net asset value, end of period	\$	31.51	\$ 32.38	\$	30.15	\$	30.23	\$	42.18
Market price, end of period	\$	31.43	\$ 32.36	\$	30.11	\$	30.15	\$	42.25
Total Return at Net Asset Value <sup>(b)</sup>		(1.63)%	11.08%		0.13%		(27.97)%		5.74%
Net assets, end of period (in 000's)	\$	40,181	\$ 43,713	\$	142,470	\$	173,824	\$	60,104
Ratio of net expenses to average net assets		0.75% <sup>(c)</sup>	0.75%		0.75%		0.75%		0.75% <sup>(c)</sup>
Ratio of net investment income to average net assets		0.64% <sup>(c)</sup>	1.10%		0.97%		0.81%		0.42% <sup>(c)</sup>
Portfolio turnover rate <sup>(d)</sup>		14%	33%		20%		15%		2%

\* Commencement of operations.

<sup>(a)</sup> Calculated based on the average shares outstanding methodology.

(b) Assumes investment at the net asset value at the beginning of the period, reinvestment of all distributions and a complete sale of the investment at the net asset value at the end of the period. Returns do not reflect the impact of taxes to shareholders relating to Fund distributions or the sale of Fund shares. Total returns for periods less than one full year are not annualized.

(c) Annualized.

(d) The Fund's portfolio turnover rate is calculated in accordance with regulatory requirements and excludes portfolio securities received or delivered as a result of in-kind transactions and short-term transactions. If such transactions were included, the Fund's portfolio turnover rate may be higher.

## Financial Highlights (continued)

Selected Data for a Share Outstanding Throughout Each Period

		Future Tech Leaders Equity ETF								
	For				e Fiscal I August 31,		For the Period September 14, 2021*			
	February 28, 2025 (Unaudited) 2024				2023	to August 31, 20				
Per Share Operating Performance:										
Net asset value, beginning of period	\$	29.89	\$	25.09	\$	24.12	\$	40.22		
Net investment income (loss) <sup>(a)</sup>		(0.03)		(0.01)		0.05		0.01		
Net realized and unrealized gain (loss)		3.00		4.88		0.92		(16.11)		
Total from investment operations		2.97		4.87		0.97		(16.10)		
Distributions to shareholders from net investment income		_		(0.07)		_(b	)	_(b)		
Net asset value, end of period	\$	32.86	\$	29.89	\$	25.09	\$	24.12		
Market price, end of period	\$	32.78	\$	29.81	\$	25.06	\$	24.08		
Total Return at Net Asset Value <sup>(c)</sup>		9.94%		19.44%		4.05%	ó	(40.03)%		
Net assets, end of period (in 000's)	\$	164,325	\$	175,575	\$	255,895	\$	242,407		
Ratio of net expenses to average net assets		0.75% <sup>(d)</sup>		0.75%		0.75%	ó	0.75% <sup>(d)</sup>		
Ratio of net investment income (loss) to average net assets		(0.21)% <sup>(d)</sup>		(0.03)%		0.19%	ó	0.03% <sup>(d)</sup>		
Portfolio turnover rate <sup>(e)</sup>		33%		48%		44%	ó	55%		

\* Commencement of operations.

<sup>(a)</sup> Calculated based on the average shares outstanding methodology.

<sup>(b)</sup> Amount is less than \$0.005 per share.

(e) Assumes investment at the net asset value at the beginning of the period, reinvestment of all distributions and a complete sale of the investment at the net asset value at the end of the period. Returns do not reflect the impact of taxes to shareholders relating to Fund distributions or the sale of Fund shares. Total returns for periods less than one full year are not annualized.

(d) Annualized.

(e) The Fund's portfolio turnover rate is calculated in accordance with regulatory requirements and excludes portfolio securities received or delivered as a result of in-kind transactions and short-term transactions. If such transactions were included, the Fund's portfolio turnover rate may be higher.

# Notes to Financial Statements

February 28, 2025 (Unaudited)

#### 1. ORGANIZATION

Goldman Sachs ETF Trust (the "Trust") is an open-end management investment company, registered under the Investment Company Act of 1940, as amended (the "Act"), consisting of multiple series. The Trust was organized as a Delaware statutory trust on December 16, 2009. The following table lists those series of the Trust that are included in this report (collectively, the "Funds" or individually a "Fund") along with their respective diversification status under the Act:

Fund	Diversified/ Non-Diversified
Goldman Sachs Future Consumer Equity ETF	Non-Diversified
Goldman Sachs Future Health Care Equity ETF	Non-Diversified
Goldman Sachs Future Planet Equity ETF	Non-Diversified
Goldman Sachs Future Tech Leaders Equity ETF	Non-Diversified

The investment objective of each Fund (except the Goldman Sachs Future Planet Equity ETF) is to seek long-term growth of capital. The investment objective of the Goldman Sachs Future Planet Equity ETF is to seek long-term capital appreciation.

Goldman Sachs Asset Management, L.P. ("GSAM"), an affiliate of Goldman Sachs & Co. LLC ("Goldman Sachs"), serves as investment adviser to the Funds pursuant to a management agreement (the "Agreement") with the Trust. Each Fund is an exchange-traded fund ("ETF"). Shares of the Funds are listed and traded on the NYSE Arca, Inc. ("NYSE Arca"). Market prices for the Funds' shares may be different from their net asset value ("NAV"). The Funds issue and redeem shares at their respective NAV only in blocks of a specified number of shares, or multiples thereof, referred to as "Creation Units". Creation Units are issued and redeemed generally for a designated portfolio of securities (including any portion of such securities for which cash may be substituted) and a specified amount of cash. Shares generally trade in the secondary market in quantities less than a Creation Unit at market prices that change throughout the day. Only those that have entered into an authorized participant agreement with ALPS Distributors, Inc. (the "Distributor") may do business directly with the Funds.

#### 2. SIGNIFICANT ACCOUNTING POLICIES

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and require management to make estimates and assumptions that may affect the reported amounts and disclosures. Actual results may differ from those estimates and assumptions. Each Fund is an investment company under GAAP and follows the accounting and reporting guidance applicable to investment companies.

A. Investment Valuation — The Funds' valuation policy is to value investments at fair value.

B. Investment Income and Investments — Investment income includes interest income, dividend income, and securities lending income, if any. Interest income is accrued daily and adjusted for amortization of premiums and accretion of discounts. Dividend income is recognized on ex-dividend date or, for certain foreign securities, as soon as such information is obtained subsequent to the ex-dividend date. Non-cash dividends, if any, are recorded at the fair market value of the securities received. Investment transactions are reflected on trade date. Realized gains and losses are calculated using identified cost. Investment transactions are recorded on the following business day for daily NAV calculations. Investment income is recorded net of any foreign withholding taxes, less any amounts reclaimable. The Funds may file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. These reclaims, if any, are reflected as other income in the Statements of Operations. Any foreign capital gains tax is accrued daily based upon net unrealized gains, and is payable upon sale of such investments. Distributions received from the Funds' investments in U.S. real estate investment trusts ("REITs") may be characterized as ordinary income, net capital gain and/or a return of capital. A return of capital is recorded by the Funds as a reduction to the cost basis of the REIT.

#### 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

C. Expenses — Expenses incurred directly by a Fund are charged to the Fund, and certain expenses incurred by the Trust are allocated across the applicable Funds on a straight-line and/or pro-rata basis, depending upon the nature of the expenses, and are accrued daily.

D. Federal Taxes and Distributions to Shareholders — It is each Fund's policy to comply with the requirements of the Internal Revenue Code of 1986, as amended (the "Code"), applicable to regulated investment companies and to distribute each year substantially all of its investment company taxable income and capital gains to its shareholders. Accordingly, each Fund is not required to make any provisions for the payment of federal income tax. Distributions to shareholders are recorded on the ex-dividend date. For Goldman Sachs Future Consumer Equity ETF, Goldman Sachs Future Health Care Equity ETF, Goldman Sachs Future Planet Equity ETF and Goldman Sachs Future Tech Leaders Equity ETF, income distributions, if any, are declared and paid annually.

Net capital losses, if any, are carried forward to future fiscal years and may be used to the extent allowed by the Code to offset any future capital gains. Losses that are carried forward will retain their character as either short-term or long-term capital losses. Utilization of capital loss carryforwards will reduce the requirement of future capital gains distributions.

The characterization of distributions to shareholders for financial reporting purposes is determined in accordance with federal income tax rules, which may differ from GAAP. The source of each Fund's distributions may be shown in the accompanying financial statements as either from distributable earnings or capital. Certain components of the Funds' net assets on the Statements of Assets and Liabilities reflect permanent GAAP/tax differences based on the appropriate tax character.

E. Foreign Currency Translation — The accounting records and reporting currency of a Fund are maintained in U.S. dollars. Assets and liabilities denominated in foreign currencies are translated into U.S. dollars using the current exchange rates at the close of each business day. The effect of changes in foreign currency exchange rates on investments is included within net realized and unrealized gain (loss) on investments. Changes in the value of other assets and liabilities as a result of fluctuations in foreign exchange rates are included in the Statements of Operations within net change in unrealized gain (loss) on foreign currency translation. Transactions denominated in foreign currencies are translated into U.S. dollars on the date the transaction occurred, the effects of which are included within net realized gain (loss) on foreign currency transactions.

### 3. INVESTMENTS AND FAIR VALUE MEASUREMENTS

U.S. GAAP defines the fair value of a financial instrument as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price); the Funds' policy is to use the market approach. GAAP establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The level in the fair value hierarchy within which the fair value measurement in its entirety falls shall be determined based on the lowest level input that is significant to the fair value measurement in its entirety. The levels used for classifying investments are not necessarily an indication of the risk associated with investing in these investments. The three levels of the fair value hierarchy are described below:

Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2 — Quoted prices in markets that are not active or financial instruments for which significant inputs are observable (including, but not limited to, quoted prices for similar investments, interest rates, foreign exchange rates, volatility and credit spreads), either directly or indirectly;

Level 3 — Prices or valuations that require significant unobservable inputs (including GSAM's assumptions in determining fair value measurement).

The Board of Trustees ("Trustees") has approved Valuation Procedures that govern the valuation of the portfolio investments held by the Funds, including investments for which market quotations are not readily available. With respect to the Funds' investments that do

# Notes to Financial Statements (continued)

February 28, 2025 (Unaudited)

#### 3. INVESTMENTS AND FAIR VALUE MEASUREMENTS (continued)

not have readily available market quotations, the Trustees have designated GSAM as the valuation designee to perform fair valuations pursuant to Rule 2a-5 under the Act (the "Valuation Designee"). GSAM has day-to-day responsibility for implementing and maintaining internal controls and procedures related to the valuation of the Funds' investments. To assess the continuing appropriateness of pricing sources and methodologies, GSAM regularly performs price verification procedures and issues challenges as necessary to third party pricing vendors or brokers, and any differences are reviewed in accordance with the Valuation Procedures.

A. Level 1 and Level 2 Fair Value Investments — The valuation techniques and significant inputs used in determining the fair values for investments classified as Level 1 and Level 2 are as follows:

Equity Securities — Equity securities traded on a United States ("U.S.") securities exchange or the NASDAQ system, or those located on certain foreign exchanges, including but not limited to the Americas, are valued daily at their last sale price or official closing price on the principal exchange or system on which they are traded. If there is no sale or official closing price or such price is believed by GSAM to not represent fair value, equity securities will be valued at the valid closing bid price for long positions and at the valid closing ask price for short positions (i.e. where there is sufficient volume, during normal exchange trading hours). If no valid bid/ask price is available, the equity security will be valued pursuant to the Valuation Procedures and consistent with applicable regulatory guidance. To the extent these investments are actively traded, they are classified as Level 1 of the fair value hierarchy, otherwise they are generally classified as Level 2. Certain equity securities containing unique attributes may be classified as Level 2.

Unlisted equity securities for which market quotations are available are valued at the last sale price on the valuation date, or if no sale occurs, at the last bid price for long positions or the last ask price for short positions, and are generally classified as Level 2.

Money Market Funds — Investments in the Goldman Sachs Financial Square Treasury Obligations Fund and Goldman Sachs Financial Square Government Fund ("Underlying Money Market Funds") are valued at the NAV per share of the Institutional Share class on the day of valuation. These investments are generally classified as Level 1 of the fair value hierarchy. For information regarding the Underlying Money Market Funds' accounting policies and investment holdings, please see the Underlying Money Market Funds' shareholder report.

B. Level 3 Fair Value Investments — To the extent that significant inputs to valuation models and other alternative pricing sources are unobservable, or if quotations are not readily available, or if GSAM believes that such quotations do not accurately reflect fair value, the fair value of a Fund's investments may be determined under the Valuation Procedures. GSAM, consistent with its procedures and applicable regulatory guidance, may make an adjustment to the most recent valuation prices of either domestic or foreign securities in light of significant events to reflect what it believes to be the fair value of the securities at the time of determining a Fund's NAV. To the extent investments are valued using single source broker quotations obtained directly from the broker or passed through from third party pricing vendors, such investments are classified as Level 3 investments.

**C.** Fair Value Hierarchy — The following is a summary of the Funds' investments classified in the fair value hierarchy as of February 28, 2025:

#### Future Consumer Equity ETF

Investment Type	Level 1	Lev	vel 2	Level 3	
Assets					
Common Stock and/or Other Equity Investments <sup>(a)</sup>					
Asia	\$ 5,731,778	\$	_	\$	
Europe	3,186,867				
North America	25,788,114		_		
South America	373,449				
Investment Company	401,970		_		
Total	\$ 35,482,178	\$	_	\$	_

### 3. INVESTMENTS AND FAIR VALUE MEASUREMENTS (continued)

Investment Type		Level 1	Level 2		Level 3	
Assets						
Common Stock and/or Other Equity Investments <sup>(a)</sup>						
Asia	\$	698,068	\$ _	- \$		
Europe		3,140,460	-	_		—
North America		16,970,639	-	_		_
Investment Company		577,206		_		
Total	\$	21,386,373	\$ _	- \$		
Future Dispet Faulty FTF						
Future Planet Equity ETF		level 1	Level 2		Level 3	
Investment Type		Level 1	Level 2		Level 3	
Investment Type Assets		Level 1	 Level 2		Level 3	
Investment Type Assets Common Stock and/or Other Equity Investments <sup>(a)</sup>	2		\$ Level 2	\$	Level 3	
Investment Type Assets Common Stock and/or Other Equity Investments <sup>(a)</sup> Asia	\$	5,700,026	\$ Level 2	- \$	Level 3	
Investment Type Assets Common Stock and/or Other Equity Investments <sup>(a)</sup> Asia Europe	\$	5,700,026 12,877,117	\$ Level 2	\$ 	Level 3	
Investment Type Assets Common Stock and/or Other Equity Investments <sup>(a)</sup> Asia	\$	5,700,026	\$ Level 2	- \$  	Level 3	

#### Future Tech Leaders Equity ETF

Investment Type	Level 1	Level 2	Level 3
Assets			
Common Stock and/or Other Equity Investments <sup>(a)</sup>			
Asia	\$ 55,124,309	\$ —	\$ —
Europe	3,968,156	—	—
North America	100,099,447	_	_
South America	2,414,688	_	
Investment Company	 2,335,596		
Total	\$ 163,942,196	\$ —	\$ —

(a) Amounts are disclosed by continent to highlight the impact of time zone differences between local market close and the calculation of NAV. Security valuations are based on the principal exchange or system on which they are traded, which may differ from country of domicile noted in table.

For further information regarding security characteristics, see the Schedules of Investments.

#### 4. AGREEMENTS AND AFFILIATED TRANSACTIONS

A. Management Agreement — Under the Agreement, GSAM manages the Funds, subject to the general supervision of the Trustees.

As compensation for the services rendered pursuant to the Agreement, the assumption of the expenses related thereto and administration of the Funds' business affairs, including providing facilities, GSAM is entitled to a management fee, accrued daily and paid monthly, equal to an annual percentage rate of each Fund's average daily net assets.

The Funds operate under a unitary management fee structure. Under the unitary fee structure, GSAM is responsible for paying substantially all the expenses of each Fund, excluding payments under a Fund's 12b-1 plan (if any), interest expenses, taxes, acquired fund fees and expenses, brokerage fees, costs of holding shareholder meetings and litigation, indemnification and extraordinary

# Notes to Financial Statements (continued)

February 28, 2025 (Unaudited)

#### 4. AGREEMENTS AND AFFILIATED TRANSACTIONS (continued)

expenses. As the Funds directly pay fees and expenses of the independent Trustees, the management fee collected by GSAM will be reduced by an amount equal to the fees and expenses paid by the Funds to the independent Trustees.

For the six months ended February 28, 2025, contractual and effective net unitary management fees with GSAM for each Fund were at the following rates:

Fund	Unitary Management Fee
Future Consumer Equity ETF	0.75%
Future Health Care Equity ETF	0.75%
Future Planet Equity ETF	0.75%
Future Tech Leaders Equity ETF	0.75%

The Funds invest in Institutional Shares of the Goldman Sachs Financial Square Treasury Obligations Fund, which is an affiliated Underlying Fund. GSAM has agreed to waive a portion of its management fee payable by the Funds in an amount equal to the management fee it earns as an investment adviser to the affiliated Underlying Fund in which the Funds invest, except those management fees it earns from the Funds' investments of cash collateral received in connection with securities lending transactions in the Goldman Sachs Financial Square Government Fund ("Government Money Market Fund"). For the six months ended February 28, 2025, GSAM waived \$832, \$387, \$468 and \$2,625 of the Funds' management fees for the Future Consumer Equity ETF, Future Health Care Equity ETF, Future Planet Equity ETF and the Future Tech Leaders Equity ETF, respectively.

**B.** Other Transactions with Affiliates — For the six months ended February 28, 2025, Goldman Sachs did not earn any brokerage commissions from portfolio transactions on behalf of the Future Consumer Equity ETF, Future Health Care Equity ETF, Future Planet Equity ETF and the Future Tech Leaders Equity ETF.

The following tables provide information about the Funds' investment in the Goldman Sachs Financial Square Treasury Obligations Fund as of and for the six months ended February 28, 2025:

#### **Future Consumer Equity ETF**

Underlying Fund	Beginning value as of August 31, 2024	Purchases at Cost	Proceeds from Sales	Ending value as of February 28, 2025	Shares as of February 28, 2025	Dividend Income
Goldman Sachs Financial Square T						
	\$ 1,466,562	\$ 7,107,831	\$ (8,172,423)	\$ 401,970	401,970	\$ 21,907
Future Health Care Equity ETF						
Underlying Fund	Beginning value as of August 31, 2024	Purchases at Cost	Proceeds from Sales	Ending value as of February 28, 2025	Shares as of February 28, 2025	Dividend Income
Goldman Sachs Financial Square T	reasury Obligations Fu	nd – Institutional S	Shares		<b>.</b>	
	206,291	1,841,331	(1,470,416)	577,206	577,206	9,651
Future Planet Equity ETF						
Underlying Fund	Beginning value as of August 31, 2024	Purchases at Cost	Proceeds from Sales	Ending value as of February 28, 2025	Shares as of February 28, 2025	Dividend Incom
Goldman Sachs Financial Square T	reasury Obligations Fu	nd – Institutional S	Shares			11,77

### 4. AGREEMENTS AND AFFILIATED TRANSACTIONS (continued)

#### Future Tech Leaders Equity ETF

Underlvina Fund	Beginning value as of August 31,	Dur	chases at Cost	Dres	ceeds from Sales		ng value as of uarv 28. 2025	Shares as of	Divida	nd Incomo
	2024	Pure	indses at Cost	PIO	Leeus from Sales	герг	uary 26, 2025	February 28, 2025	Divide	nd Income
Goldman Sachs Financial Square Treasur	y Obligations Fu	nd –	Institutional S	hare	s					
	\$ 2,572,821	\$	16,220,247	\$	(16,457,472)	\$	2,335,596	2,335,596	\$	65,984

#### 5. CREATION AND REDEMPTION OF CREATION UNITS

The Trust issues and redeems shares of the Funds only in Creation Units on a continuous basis through the Distributor, without an initial sales load, at NAV next determined after receipt, on any Business Day (as defined in the Statement of Additional Information), of an order in proper form. Shares of the Funds may only be purchased or redeemed by certain financial institutions (each an "Authorized Participant"). An Authorized Participant is either (1) a "Participating Party" or other participant in the clearing process through the Continuous Net Settlement System of the National Securities Clearing Corporation; or (2) a Depository Trust Company participant; which, in either case, must have executed an agreement with the Distributor. Retail investors will typically not qualify as an Authorized Participant or have the resources to buy and sell whole Creation Units. Therefore, they will be unable to purchase or redeem the shares directly from the Funds. Rather, most retail investors will purchase shares in the secondary market at market prices with the assistance of a broker and may be subject to customary brokerage commissions or fees. Fixed creation and redemption transaction fees are imposed in connection with creations and redemptions.

Authorized Participants transacting in Creation Units for cash may also pay a variable charge to compensate the relevant fund for certain transaction costs (e.g. taxes on currency or other financial transactions, and brokerage costs) and market impact expenses relating to investing in portfolio securities. Such variable charges, if any, are included in "Proceeds from sale of shares" in the Statements of Changes in Net Assets.

Share activity is as follows:

		Gole	lman Sachs Future Con	sumer Equity ETF		
	For th Six Months February 20 (Unaudi	Endec 8, 2025	-	For the F Year Ended Augu		
	Shares	Dollars		Shares	Dollars	
Fund Share Activity						
Shares sold	_	\$	_	775,000	\$ 20,844,686	
Shares redeemed	(850,000)		(29,939,770)	(4,675,000)	(128,695,327)	
NET DECREASE IN SHARES	(850,000)	\$	(29,939,770)	(3,900,000)	\$ (107,850,641)	

		Goldman Sachs Future Health Care Equity ETF							
	For th Six Months February 24 (Unaudi	Ended 3, 2025		For the Fiscal Year Ended August 31, 2024					
	Shares	Shares Dollars			Shares Dollars				
Fund Share Activity									
Shares redeemed	(25,000)	\$	(827,726)	(2,800,000)	\$	(80,716,187)			
NET DECREASE IN SHARES	(25,000)	\$	(827,726)	(2,800,000)	\$	(80,716,187)			

# Notes to Financial Statements (continued)

February 28, 2025 (Unaudited)

## 5. CREATION AND REDEMPTION OF CREATION UNITS (continued)

		Goldman Sachs Future Planet Equity ETF							
	Six Months February 2	For the Six Months Ended February 28, 2025 (Unaudited)				For the Fiscal Year Ended August 31, 2024			
	Shares		Dollars	Shares	Dollars				
Fund Share Activity									
Shares redeemed	(75,000)	\$	(2,409,005)	(3,375,000)	\$	(91,661,802)			
NET DECREASE IN SHARES	(75,000)	\$	(2,409,005)	(3,375,000)	\$	(91,661,802)			

		Goldman Sachs Future Tech Leaders Equity ETF								
	For th Six Months February 28 (Unaudii	Ended 3, 2025	-	For the Fi Year Ended Augu		, 2024				
	Shares		Dollars	Shares		Dollars				
Fund Share Activity										
Shares sold	75,000	\$	2,674,565	525,000	\$	12,937,052				
Shares redeemed	(950,000)		(29,875,904)	(4,850,000)		(117,490,811)				
NET DECREASE IN SHARES	(875,000)	\$	(27,201,339)	(4,325,000)	\$	(104,553,759)				

### 6. PORTFOLIO SECURITIES TRANSACTIONS

The cost of purchases and proceeds from sales and maturities of long-term securities for the six months ended February 28, 2025 were as follows:

Fund	Purchases	Sales		
Future Consumer Equity ETF	\$ 12,212,121 \$	17,261,513		
Future Health Care Equity ETF	5,103,254	5,206,477		
Future Planet Equity ETF	5,836,757	6,359,621		
Future Tech Leaders Equity ETF	55,161,855	62,793,027		

The purchases and sales from in-kind creation and redemption transactions for the six months ended February 28, 2025 were as follows:

Fund	Pu	rchases	Sales		
Future Consumer Equity ETF	\$	— \$	24,443,226		
Future Health Care Equity ETF		_	815,946		
Future Planet Equity ETF		_	2,206,474		
Future Tech Leaders Equity ETF		2,149,720	22,639,215		

### 7. SECURITIES LENDING

The Funds may lend their securities through a securities lending agent, the Bank of New York Mellon ("BNYM"), to certain qualified borrowers. In accordance with the Funds' securities lending procedures, the Funds receive cash collateral at least equal

#### 7. SECURITIES LENDING (continued)

to the market value of the securities on loan. The market value of the loaned securities is determined at the close of business of the Funds, at their last sale price or official closing price on the principal exchange or system on which they are traded, and any additional required collateral is delivered to the Funds on the next business day. As with other extensions of credit, the Funds may experience delay in the recovery of their securities or incur a loss should the borrower of the securities breach its agreement with the Funds or become insolvent at a time when the collateral is insufficient to cover the cost of repurchasing securities on loan. Dividend income received from securities on loan may not be subject to withholding taxes and therefore withholding taxes paid may differ from the amounts listed in the Statements of Operations. Loans of securities are terminable at any time and as such 1) the remaining contractual maturities of the outstanding securities lending transactions are considered to be overnight and continuous and 2) the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions. The Funds invest the cash collateral received in connection with securities lending transactions in the Goldman Sachs Financial Square Government Fund ("Government Money Market Fund"), an affiliated series of the Goldman Sachs Trust. The Government Money Market Fund is registered under the Act as an open end investment company, is subject to Rule 2a-7 under the Act, and is managed by GSAM, for which GSAM may receive a management fee of up to 0.16% on an annualized basis of the average daily net assets of the Government Money Market Fund.

In the event of a default by a borrower with respect to any loan, BNYM may exercise any and all remedies provided under the applicable borrower agreement to make the Funds whole. These remedies include purchasing replacement securities by applying the collateral held from the defaulting broker against the purchase cost of the replacement securities. If BNYM is unable to purchase replacement securities, BNYM will indemnify the Funds by paying the Funds an amount equal to the market value of the securities loaned minus the value of cash collateral received from the borrower for the loan, subject to an exclusion for any shortfalls resulting from a loss of value in such cash collateral due to reinvestment risk. The Funds' master netting agreements with certain borrowers provide the right, in the event of a default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate net exposure to the defaulting party or request additional collateral. However, in the event of a default by a borrower, a resolution authority could determine that such rights are not enforceable due to the restrictions or prohibitions against the right of set-off that may be imposed in accordance with a particular jurisdiction's bankruptcy or insolvency laws. The Funds' loaned securities were all subject to enforceable Securities Lending Agreements and the value of the collateral was at least equal to the value of the cash received. The amounts of the Funds' overnight and continuous agreements, which represent the gross amounts of recognized liabilities for securities lending transactions outstanding as of February 28, 2025, are disclosed as "Payable upon return of securities loaned" on the Statements of Assets and Liabilities, where applicable. The Future Health Care Equity ETF and Future Tech Leaders Equity ETF did not have securities on loan as of February 28, 2025.

Each of the Funds and BNYM received compensation relating to the lending of the Funds' securities. The amounts earned, if any, by the Funds for the six months ended February 28, 2025 are reported under Investment Income on the Statements of Operations.

The following table provides information about the Funds' investment in the Government Money Market Fund for the six months ended February 28, 2025:

Fund	Beginning value as of August 31, 2024	Purchases at Cost	Proceeds from Sales	Ending value as of February 28, 2025	
Future Consumer Equity ETF	\$ 193,353	\$ 144,866	\$ (338,219)	\$	
Future Health Care Equity ETF	_	105,316	(105,316)	_	
Future Planet Equity ETF	19,140	4,849,003	(4,859,823)	8,320	
Future Tech Leaders Equity ETF	_	5,804,576	(5,804,576)	_	

#### 8. TAX INFORMATION

As of the Funds' most recent fiscal year end, August 31, 2024, the Funds' capital loss carryforwards and certain timing differences on a tax-basis were as follows:

# Notes to Financial Statements (continued)

February 28, 2025 (Unaudited)

#### 8. TAX INFORMATION (continued)

	Fi	Future Consumer Equity ETF		Future Health Care Equity ETF		Future Planet Equity ETF		Future Tech Leaders Equity ETF	
Capital loss carryforwards:									
Perpetual Short-Term	\$	(5,562,105)	\$	(8,772,787)	\$	(1,463,602)	\$	(47,059,327)	
Perpetual Long-Term		(6,765,273)		(6,256,885)		(7,923,919)		(53,821,144)	
Total capital loss carryforwards		(12,327,378)		(15,029,672)		(9,387,521)		(100,880,471)	
Timing differences — (Qualified Late Year Ordinary Loss Deferral/									
Post October Capital Loss Deferral)		(3,161,584)		(1,456,157)		(9,966,801)		(23,485,730)	

As of February 28, 2025, the Fund's aggregate security unrealized gains and losses based on cost for U.S. federal income tax purposes were as follows:

	Fu	ture Consumer Equity ETF	Fut	Future Health Care Future Planet Equity Equity ETF ETF		Future Tech Leaders Equity ETF		
Tax Cost	\$	30,533,110	\$	19,366,101	\$	44,549,186	\$	146,007,053
Gross unrealized gain		7,461,380		3,996,396		3,996,206		29,433,755
Gross unrealized loss		(2,512,312)		(1,976,124)		(8,925,575)		(11,498,612)
Net unrealized gain (loss)	\$	4,949,068	\$	2,020,272	\$	(4,929,369)	\$	17,935,143

The difference between GAAP-basis and tax basis unrealized gains (losses) is attributable primarily to wash sales, differences in the tax treatment of partnership investments and passive foreign investment company investments.

GSAM has reviewed the Funds' tax positions for all open tax years (the current and prior years, as applicable) and has concluded that no provision for income tax is required in the Funds' financial statements. Such open tax years remain subject to examination and adjustment by tax authorities.

#### 9. OTHER RISKS

The Funds' risks include, but are not limited to, the following:

Foreign and Emerging Countries Risk — Investing in foreign markets may involve special risks and considerations not typically associated with investing in the U.S. Foreign securities may be subject to risk of loss because of more or less foreign government regulation; less public information; less stringent investor protections; less stringent accounting, corporate governance, financial reporting and disclosure standards; and less economic, political and social stability in the countries in which a Fund invests. The imposition of sanctions, exchange controls (including repatriation restrictions), confiscation of assets and property, trade restrictions (including tariffs) and other government restrictions by the U.S. or other governments, or from problems in registration, settlement or custody, may also result in losses. The type and severity of sanctions and other similar measures, including counter sanctions and other retaliatory actions, that may be imposed could vary broadly in scope, and their impact is impossible to predict. For example, the imposition of sanctions and other similar measures could, among other things, cause a decline in the value and/or liquidity of securities issued by the sanctioned country or companies located in or economically tied to the sanctioned country and increase market volatility and disruption in the sanctioned country and throughout the world. Sanctions and other similar measures could limit or prevent a Fund from buying and selling securities (in the sanctioned country and other markets), significantly delay or prevent the settlement of securities transactions, and significantly impact a Fund's liquidity and performance. Foreign risk also involves the risk of negative foreign currency exchange rate fluctuations, which may cause the value of securities denominated in such foreign currency (or other instruments through which a Fund has exposure to foreign currencies) to decline in value. Currency

#### 9. OTHER RISKS (continued)

exchange rates may fluctuate significantly over short periods of time. To the extent that a Fund also invests in securities of issuers located in, or economically tied to, emerging markets, these risks may be more pronounced.

Foreign Custody Risk — The Funds invest in foreign securities, and as such the Funds may hold such securities and cash with foreign banks, agents, and securities depositories appointed by a Fund's custodian (each a "Foreign Custodian"). Some foreign custodians may be recently organized or new to the foreign custody business. In some countries, Foreign Custodians may be subject to little or no regulatory oversight over, or independent evaluation of, their operations. Further, the laws of certain countries may place limitations on a Fund's ability to recover its assets if a Foreign Custodian enters bankruptcy. Investments in emerging markets may be subject to even greater custody risks than investments in more developed markets. Custody services in emerging market countries are very often undeveloped and may be considerably less well regulated than in more developed countries, and thus may not afford the same level of investor protection as would apply in developed countries.

**Geographic Risk** — If a Fund focuses its investments in securities of issuers located in a particular country or geographic region, the Fund may be subjected, to a greater extent than if its investments were less focused, to the risks of volatile economic cycles and/or conditions and developments that may be particular to that country or region, such as: adverse securities markets; adverse exchange rates; adverse social, political, regulatory, economic, business, environmental or other developments; or natural disasters.

Investment Style Risk — Different investment styles (e.g., growth, value or quantitative) tend to shift in and out of favor depending upon market and economic conditions and investor sentiment. The Fund may outperform or underperform other funds that invest in similar asset classes but employ different investment styles.

**Issuer Concentration Risk** — The Funds may invest in a relatively small number of issuers. As a result, they may be subject to greater risks than a fund that invests in a greater number of issuers. A change in the value of any single investment held by the Funds may affect the overall value of the Funds more than it would affect a mutual fund that holds more investments. In particular, the Funds may be more susceptible to adverse developments affecting any single issuer in the Funds and may be susceptible to greater losses because of these developments.

Large Shareholder Transaction Risk — Certain shareholders, including other funds advised by the Investment Adviser, may from time to time own a substantial amount of the Fund's Shares. In addition, a third party investor, the Investment Adviser or an affiliate of the Investment Adviser, an authorized participant, a lead market maker, or another entity (i.e., a seed investor) may invest in the Fund and hold its investment solely to facilitate commencement of the Fund or to facilitate the Fund's achieving a specified size or scale. Any such investment may be held for a limited period of time. There can be no assurance that any large shareholder would not redeem its investment, that the size of the Fund would be maintained at such levels or that the Fund would continue to meet applicable listing requirements. Redemptions by large shareholders could have a significant negative impact on the Fund, including on the Fund's liquidity. In addition, transactions by large shareholders may account for a large percentage of the trading volume on NYSE Arca and may, therefore, have a material upward or downward effect on the market price of the Shares.

Market and Credit Risks — In the normal course of business, a Fund trades financial instruments and enters into financial transactions where risk of potential loss exists due to changes in the market (market risk). The value of the securities in which a Fund invests may go up or down in response to the prospects of individual companies, particular sectors or governments and/or general economic conditions throughout the world due to increasingly interconnected global economies and financial markets. Events such as war, military conflict, geopolitical disputes, acts of terrorism, social or political unrest, natural disasters, recessions, inflation, rapid interest rate changes, supply chain disruptions, tariffs and other restrictions on trade, sanctions or the spread of infectious illness or other public health threats, or the threat or potential of one or more such events and developments, could also significantly impact a Fund and its investments. Additionally, a Fund may also be exposed to credit risk in the event that an issuer or guarantor fails to perform or that an institution or entity with which the Fund has unsettled or open transactions defaults.

Market Trading Risk — Each Fund faces numerous market trading risks, including disruptions to creations and redemptions, the existence of extreme market volatility or potential lack of an active trading market for Shares. If a shareholder purchases Shares at a time when the market price is at a premium to the NAV or sells Shares at a time when the market price is at a discount to the NAV, the shareholder may pay more for, or receive less than, the underlying value of the Shares, respectively. The Investment Adviser

# Notes to Financial Statements (continued)

February 28, 2025 (Unaudited)

#### 9. OTHER RISKS (continued)

cannot predict whether Shares will trade below, at or above their NAV. Price differences may be due, in large part, to the fact that supply and demand forces at work in the secondary trading market for Shares will be closely related to, but not identical to, the same forces influencing the prices of the securities of a Fund's Index trading individually or in the aggregate at any point in time.

Mid-Cap and Small-Cap Risk — Investments in mid-capitalization and small-capitalization companies involve greater risks than those associated with larger, more established companies. These securities may be subject to more abrupt or erratic price movements and may lack sufficient market liquidity, and these issuers often face greater business risks.

Non-Diversification Risk — The Funds are non-diversified, meaning that they are permitted to invest a larger percentage of their assets in one or more issuers or in fewer issuers than diversified funds. Thus, a Fund may be more susceptible to adverse developments affecting any single issuer held in its portfolio, and may be more susceptible to greater losses because of these developments.

Seed Investor Risk — GSAM and/or its affiliates may make payments to one or more investors that contribute seed capital to the Fund. Such payments may continue for a specified period of time and/or until a specified dollar amount is reached. Those payments will be made from the assets of GSAM and/or such affiliates (and not the Fund). There is a risk that such seed investors may redeem their investments in the Fund, particularly after payments from GSAM and/or its affiliates have ceased. As with redemptions by other large shareholders, such redemptions could have a significant negative impact on the Fund, including on the Fund's liquidity and the market price of the Fund's Shares.

Thematic Investing Risk — The Fund's thematic investment strategy limits the universe of investment opportunities available to the Fund and will affect the Fund's exposure to certain companies, sectors, regions, and countries, which may result in the Fund forgoing opportunities to buy or sell certain securities when it might otherwise be advantageous to do so. Adhering to the Fund's thematic investment strategy may also affect the Fund's performance relative to similar funds that do not seek to invest in companies exposed to certain themes. There is no guarantee that the Investment Adviser's views, security selection criteria or investment judgment will reflect the beliefs or values of any particular investor. In addition, the Investment Adviser is not required to monitor on an ongoing basis whether a current holding continues to be aligned with one or more themes or otherwise associated with certain themes. The Fund is not required to sell, and may instead add to, positions in holdings that no longer continue to be aligned with one or more of the Key Themes or associated with these themes.

#### 10. INDEMNIFICATIONS

Under the Trust's organizational documents, its Trustees, officers, employees and agents are indemnified, to the extent permitted by the Act and state law, against certain liabilities that may arise out of performance of their duties to the Funds. Additionally, in the course of business, the Funds enter into contracts that contain a variety of indemnification clauses. The Funds' maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Funds that have not yet occurred. However, GSAM believes the risk of loss under these arrangements to be remote.

#### **11. OTHER MATTERS**

The Funds adopted Financial Accounting Standards Board Accounting Standards Update 2023-07, Segment Reporting (Topic 280) -Improvements to Reportable Segment Disclosures. Each Fund operates in one segment. The segment derives its revenues from Fund investments made in accordance with the defined investment strategy of the Fund, as prescribed in the Funds' prospectus. The Chief Operating Decision Maker ("CODM") is the Investment Adviser. The CODM monitors and actively manages the operating results of each Fund. The financial information the CODM leverages to assess the segment's performance and to make decisions for the Funds' single segment, is consistent with that presented within each Fund's financial statements.

## 12. SUBSEQUENT EVENTS

Subsequent events have been evaluated through the date of issuance, and GSAM has concluded that there is no impact requiring adjustment or disclosure in the financial statements.

## TRUSTEES

Gregory G. Weaver, *Chair* Cheryl K. Beebe Dwight L. Bush Kathryn A. Cassidy John G. Chou Joaquin Delgado Eileen H. Dowling Lawrence Hughes John F. Killian Steven D. Krichmar Michael Latham James A. McNamara Lawrence W. Stranghoener

## THE BANK OF NEW YORK MELLON

Transfer Agent

## **ALPS DISTRIBUTORS, INC.**

Distributor

## **GOLDMAN SACHS ASSET MANAGEMENT, L.P.**

Investment Adviser 200 West Street, New York, New York 10282

## **OFFICERS**

James A. McNamara, *President* Joseph F. DiMaria, *Principal Financial Officer, Principal Accounting Officer and Treasurer* Robert Griffith, *Secretary*